

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 October 2002 (24.10.2002)

PCT

(10) International Publication Number
WO 02/083888 A2

- (51) International Patent Classification⁷: C12N 15/00 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/EP02/04322
- (22) International Filing Date: 18 April 2002 (18.04.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
01201407.2 18 April 2001 (18.04.2001) EP
- (71) Applicant (*for all designated States except US*):
VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW [BE/BE]; Rijvisschestraat 120, B-9052 Zwijnaarde (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): GOOSSENS, Alain [BE/BE]; Markt 36, B-9160 Lokeren (BE). INZÉ, Dirk [BE/BE]; Gustaaf Driesstraat 18, B-9310 Moorsel - Aalst (BE).
- (74) Common Representative: VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW; Rijvisschestraat 120, B-9052 Zwijnaarde (BE).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/083888 A2

(54) Title: THE USE OF GENES ENCODING MEMBRANE TRANSPORTER PUMPS TO STIMULATE THE PRODUCTION OF SECONDARY METABOLITES IN BIOLOGICAL CELLS

(57) Abstract: The current invention relates to the field of secondary metabolite production in plants and plant cell cultures. More specifically, the invention relates to the use of transporters and more particularly ABC-transporters to enhance the production and/or secretion of secondary metabolites in plants and plant cell cultures.

The use of genes encoding membrane transporter pumps to stimulate the production of secondary metabolites in biological cells

Field of the invention

5 The current invention relates to the field of secondary metabolite production in plants and plant cell cultures. More specifically, the invention relates to the use of transporters and more particularly ABC-transporters to enhance the production and/or secretion of secondary metabolites in plants and plant cell cultures.

10 **Introduction to the invention**

Higher plants are able to produce a large number of small-molecular-weight compounds with very complex structures. These compounds, called secondary metabolites, play for example a role in the resistance against pests and diseases, attraction of pollinators and interaction with symbiotic microorganisms. Besides the 15 importance for the plant itself, secondary metabolites are of great interest because they determine the quality of food (colour, taste, aroma) and ornamental plants (flower colour, smell). A number of secondary metabolites isolated from plants are commercially available as fine chemicals, for example, drugs, dyes, flavours, fragrances and even pesticides. In addition, various health improving effects and 20 disease preventing activities of secondary metabolites have been discovered, such as anti-oxidative and anti-metastatic-lowering properties (e.g. vinblastine, taxol). Although about 100.000 plant secondary metabolites are already known, only a small percentage of all plants have been studied to some extent for the presence of 25 secondary metabolites. It is expected that interest in such metabolites will continue to grow as e.g. plant sources of new and useful drugs are discovered. Some of these valuable phytochemicals are quite expensive because they are only produced at extremely low levels in plants. Very little is known about the biosynthesis of secondary metabolites in plants. However, some recently elucidated biosynthetic pathways of 30 secondary metabolites are long and complicated requiring multiple enzymatic steps to produce the desired end product. Most often, the alternative of producing these secondary metabolites through chemical synthesis is complicated due to a large number of asymmetric carbons and in most cases chemical synthesis is not economically feasible.

The recovery of valuable secondary metabolites is mostly achieved through extraction and purification (generally at low yields) of imported, sometimes exotic, plant biomasses, whose reproductive agriculture and secure long term supply are often very difficult, if not impossible to guarantee. The problems of obtaining useful metabolites from natural sources may potentially be circumvented by cell culture. The culture of plant cells has been explored since the 1960's as a viable alternative for the production of complex phytochemicals of industrial interest. Although plant cell cultures might be somewhat sensitive for shear forces, many cultures can be grown in large bioreactors without difficulty. For example, the use of large-scale plant cell cultures in bioreactors for the production of alkaloids has been extensively studied (Verpoorte et al. (1999) *Biotechnol. Lett.* 21, 467). Since it has been observed that undifferentiated cultures such as callus and cell suspension cultures produce only very low levels of secondary metabolites one tends to use differentiated plant cell cultures such as root- and hairy root-culture. For example, tropane alkaloids that are only scarcely synthesized in undifferentiated cells are produced at relatively high levels in cultured roots. Despite the promising features and developments, the production of plant-derived pharmaceuticals by plant cell cultures has not been fully commercially exploited. The main reasons for this reluctance shown by industry to produce secondary metabolites by means of cell cultures, compared to the conventional extraction of whole plant material, are economical ones based on the slow growth and the low production levels of secondary metabolites by such plant cell cultures. Important causes are the toxicity of such compounds to the plant cell, and the role of catabolism of the secondary metabolites. Another important problem is that secondary metabolites are mostly retained intracellularly complicating the downstream processing and purification. Indeed, often laborious extraction schemes have to be developed for each specific secondary metabolite of interest.

It is an objective of the current invention to provide a solution to these problems. The invention aims primarily at using genes encoding ABC-transporters to enhance the production of secondary metabolites in plant cell cultures. ABC-transporters are well known in the field of cancer therapy as molecular 'pumps' in tumour-cell membranes that actively expel chemotherapy drugs from the interior of the cells. This allows tumour cells to avoid the toxic effects of the drug or molecular processes within the nucleus or the cytoplasm. The two pumps commonly found to confer chemoresistance in cancer are P-glycoprotein and the so-called multidrug resistance-associated protein

(MRP). In addition, ABC-transporters have been used in plants as a selection marker (WO 99/10514) and for the protection of plants for the detrimental effects of certain exogenously added xenobiotics (WO 00/18886, Muhitch J.M. et al. (2000) *Plant Science*, 157, 201). In US patent 6,166,290 it is shown that the use of ABC-
5 transporters in plants can be used to stimulate remediation, to strengthen the disease response and to modulate plant pigmentation. It has however never been shown in the art that ABC-transporters can be used to enhance the level of secondary metabolites made in plant cell cultures neither has it been shown that ABC-transporters can be used to stimulate the secretion of endogenously synthesized secondary metabolites
10 from the inside of plant cells to the extracellular space.

Legends of Figures

- Fig. 1: Plasmid map of the pK7WGD2 binary vector.
15 Fig. 2: Hyoscyamine-induced cell death in transformed BY-2 cells.
Three-day old transformed BY-2 cell cultures were incubated in the absence (CON) or presence (HYO) of 30 mM hyoscyamin for 24 hours. Cell death was assayed at two timepoints (6 hours and 24 hours) by Evans blue staining and is indicated as the fold
20 increase in optical density at OD₆₀₀ relative to the value at the start of the experiment. Values are the mean of three independent experiments. GUS, US50, W303 and AT represent BY-2 cell lines transformed with pK7WGD2-GUS, pK7WGD2-ScPDR5-US50, pK7WGD2-ScPDR5-W303 and pK7WGD2-AtPDR1 respectively.
25 Fig. 3 : *HmPDR1* expression is induced by CdCl₂.
Quantitative RT-PCR analysis of *HmPDR1* in total RNA from *H. muticus* hairy roots treated with 1mM CdCl₂ or H₂O as a control. Ethidium bromide-stained rRNA is used as a control. The fold increase in the ratio of *HmPDR1* transcript to rRNA fluorescence, relative to the value at timepoint zero, is given below the panels. Time after elicitation
30 is indicated in hours.

Aims and detailed description of the invention

The human species has always been interested in plant secondary metabolites for flavourings for food, perfumes, pigments for artwork and clothing, and tools to achieve

spiritual enlightenment. Furthermore, plant derived drugs are among the oldest drugs in medicine. Many plants belonging to, for example, the *Solanaceae* family have been used for centuries because of their active substances: hyoscyamine and scopolamine. Also other *Solanaceae* plants belonging to the genera *Atropa*, *Datura*, *Duboisia* and 5 *Scopolia* produce these valuable alkaloids. In medicine they find important applications in ophthalmology, anaesthesia, and in the treatment of cardiac and gastrointestinal diseases. In addition to their peripheral anticholinergic effects they also act on the central nervous system and are used to relieve the symptoms of Parkinson's disease, and as antidotes for the anticholinesterases such as organophosphates. Cocaine, 10 which has strong stimulant effects on the central nervous system and is used as a topical anaesthetic, is also a tropane alkaloid but is found outside *Solanaceae* in *Erythroxylum coca*. Although a lot of information is available on the pharmacological effects of tropane alkaloids, surprisingly little is known about how the plants synthesize these substances and almost nothing is known about how this synthesis is regulated. 15 Progress in the elucidation of the biosynthetic pathways of plant secondary products has long been hampered by lack of good model systems. In the past two decades plant cell cultures have proven to be invaluable tools in the investigation of plant secondary metabolite biosynthetic pathways. Plant cell and tissue cultures have also been widely used in order to obtain alternative production systems of tropane alkaloids 20 as described above. The main problem has usually been a lack of a sufficient amount of alkaloids and/or instability of the production. Many cultures have shown a decrease in productivity with time. Current approaches to resolve some of the above described problems comprise: (1) the optimisation of the growth conditions of plant cell cultures (US 6,069,009), (2) the metabolic engineering of secondary metabolism by 25 overexpression of regulatory genes (e.g. transcription factors) that induce the pathway (WO 00/46383) and (3) the stimulation of secondary metabolism by the use of elicitors (US 5,552,307). In the present invention we have identified an important bottleneck for the production of secondary metabolites in plants and plant cell cultures. We have found that production of secondary metabolites in plants and plant cell cultures can be 30 enhanced by the transformation of a gene encoding a transporter to the plants or plant cells producing the desired secondary metabolite. Sometimes the slow growth of plant cells producing secondary metabolites is due to the toxicity of the metabolites which are produced inside the plant cells. We have shown that the toxicity can to a large extent be reduced by the transformation of a gene encoding a transporter to the plant

cells producing the desired secondary metabolite. Consequently, due to the reduction of the toxicity there is a higher growth rate of the transformed plant cell culture.

- The present invention accordingly provides in one embodiment a method for inducing or enhancing the production or the secretion of at least one secondary metabolite in biological cells by transformation of said biological cells with an expression vector comprising an expression cassette that further comprises a gene coding for a transporter. With "at least one secondary metabolite" it is meant related structures of secondary metabolites and intermediates or precursors thereof. Said biological cells can be plant cells, fungal cells, bacteria cells, algae cells and/or animal cells. A "transporter" is a protein capable of interacting with at least one specific secondary metabolite and transporting said metabolite across a membrane wherein said membrane comprises the vacuolar membrane (tonoplast), or chloroplast membrane or plasmamembrane. Said transporter gene can be heterologous or homologous to the biological cell.
- "Expression cassettes", of the present invention are generally DNA constructs preferably including (5' to 3' in the direction of transcription): a promoter region, a gene encoding for a transporter operatively linked with the transcription initiation region, and a termination sequence including a stop signal for RNA polymerase and a polyadenylation signal. It is understood that all of these regions should be capable of operating in the biological cells to be transformed. The promoter region comprising the transcription initiation region, which preferably includes the RNA polymerase binding site, and the polyadenylation signal may be native to the biological cell to be transformed or may be derived from an alternative source, where the region is functional in the biological cell.
- The transporters of this invention may be expressed in for example a plant cell under the control of a promoter that directs constitutive expression or regulated expression. Regulated expression comprises temporally or spatially regulated expression and any other form of inducible or repressible expression. Temporally means that the expression is induced at a certain time point, for instance, when a certain growth rate of the plant cell culture is obtained (e.g. the promoter is induced only in the stationary phase or at a certain stage of development). Spatially means that the promoter is only active in specific organs, tissues, or cells (e.g. only in roots, leaves, epidermis, guard cells or the like. Other examples of regulated expression comprise promoters whose activity is induced or repressed by adding chemical or physical stimuli to the plant cell.

In a preferred embodiment the expression of the transporters is under control of environmental, hormonal, chemical, and/or developmental signals, also can be used for expression of transporters in plant cells, including promoters regulated by (1) heat, (2) light, (3) hormones, such as abscisic acid and methyl jasmonate (4) wounding or 5 (5) chemicals such as salicylic acid, chitosans or metals. Indeed, it is well known that the expression of secondary metabolites can be boosted by the addition of for example specific chemicals, jasmonate and elicitors. The co-expression of transporters, in combination with a stimulation of secondary metabolite synthesis is beneficial for an optimal and enhanced production of secondary metabolites. Alternatively, the 10 transporters can be placed under the control of a constitutive promoter. A constitutive promoter directs expression in a wide range of cells under a wide range of conditions. Examples of constitutive plant promoters useful for expressing heterologous polypeptides in plant cells include, but are not limited to, the cauliflower mosaic virus (CaMV) 35S promoter, which confers constitutive, high-level expression in most plant 15 tissues including monocots; the nopaline synthase promoter and the octopine synthase promoter.

The expression cassette is usually provided in a DNA or RNA construct which is typically called an "expression vector" which is any genetic element, e.g., a plasmid, a chromosome, a virus, behaving either as an autonomous unit of polynucleotide 20 replication within a cell (i.e. capable of replication under its own control) or being rendered capable of replication by insertion into a host cell chromosome, having attached to it another polynucleotide segment, so as to bring about the replication and/or expression of the attached segment. Suitable vectors include, but are not limited to, plasmids, bacteriophages, cosmids, plant viruses and artificial 25 chromosomes. The expression cassette may be provided in a DNA construct which also has at least one replication system. In addition to the replication system, there will frequently be at least one marker present, which may be useful in one or more hosts, or different markers for individual hosts. The markers may a) code for protection against a biocide, such as antibiotics, toxins, heavy metals, certain sugars or the like; 30 b) provide complementation, by imparting prototrophy to an auxotrophic host; or c) provide a visible phenotype through the production of a novel compound in the plant. Exemplary genes which may be employed include neomycin phosphotransferase (NPTII), hygromycin phosphotransferase (HPT), chloramphenicol acetyltransferase (CAT), nitrilase, and the gentamicin resistance gene. For plant host selection, non-

limiting examples of suitable markers are β -glucuronidase, providing indigo production, luciferase, providing visible light production, Green Fluorescent Protein and variants thereof, NPTII, providing kanamycin resistance or G418 resistance, HPT, providing hygromycin resistance, and the mutated aroA gene, providing glyphosate resistance.

- 5 The term "promoter activity" refers to the extent of transcription of a gene that is operably linked to the promoter whose promoter activity is being measured. The promoter activity may be measured directly by measuring the amount of RNA transcript produced, for example by Northern blot or indirectly by measuring the product coded for by the RNA transcript, such as when a reporter gene is linked to the
10 promoter. The term "operably linked" refers to linkage of a DNA segment to another DNA segment in such a way as to allow the segments to function in their intended manners. A DNA sequence encoding a gene product is operably linked to a regulatory sequence when it is ligated to the regulatory sequence, such as, for example a promoter, in a manner which allows modulation of transcription of the DNA sequence,
15 directly or indirectly. For example, a DNA sequence is operably linked to a promoter when it is ligated to the promoter downstream with respect to the transcription initiation site of the promoter and allows transcription elongation to proceed through the DNA sequence. A DNA for a signal sequence is operably linked to DNA coding for a polypeptide if it is expressed as a pre-protein that participates in the transport of the
20 polypeptide. Linkage of DNA sequences to regulatory sequences is typically accomplished by ligation at suitable restriction sites or adapters or linkers inserted in lieu thereof using restriction endonucleases known to one of skill in the art.

The term "heterologous DNA" or "heterologous RNA" refers to DNA or RNA that does not occur naturally as part of the genome or DNA or RNA sequence in which it is
25 present, or that is found in a cell or location in the genome or DNA or RNA sequence that differs from that which is found in nature. Heterologous DNA and RNA (in contrast to homologous DNA and RNA) are not endogenous to the cell into which it is introduced, but has been obtained from another cell or synthetically or recombinantly produced. An example is a human gene, encoding a human protein, operably linked to
30 a non-human promoter. Another example is a gene isolated from one plant species operably linked to a promoter isolated from another plant species. Generally, though not necessarily, such DNA encodes RNA and proteins that are not normally produced by the cell in which the DNA is transcribed or expressed. Similarly exogenous RNA encodes for proteins not normally expressed in the cell in which the exogenous RNA is

present. Heterologous DNA or RNA may also refer to as foreign DNA or RNA. Any DNA or RNA that one of skill in the art would recognize as heterologous or foreign to the cell in which it is expressed is herein encompassed by the term heterologous DNA or heterologous RNA. Examples of heterologous DNA include, but are not limited to,

5 DNA that encodes proteins, polypeptides, receptors, reporter genes, transcriptional and translational regulatory sequences, selectable or traceable marker proteins, such as a protein that confers drug resistance, RNA including mRNA and antisense RNA and ribozymes.

Generally, two basic types of metabolites are synthesised in cells, i.e. those referred to

10 as primary metabolites and those referred to as secondary metabolites. A primary metabolite is any intermediate in, or product of the primary metabolism in cells. The primary metabolism in cells is the sum of metabolic activities that are common to most, if not all, living cells and are necessary for basal growth and maintenance of the cells. Primary metabolism thus includes pathways for generally modifying and synthesising

15 certain carbohydrates, proteins, fats and nucleic acids, with the compounds involved in the pathways being designated primary metabolites. In contrast hereto, secondary metabolites usually do not appear to participate directly in growth and development. They are a group of chemically very diverse products that often have a restricted taxonomic distribution. Secondary metabolites normally exist as members of closely

20 related chemical families, usually of a molecular weight of less than 1500 Dalton, although some bacterial toxins are considerably longer. Secondary plant metabolites include e.g. alkaloid compounds (e.g. terpenoid indole alkaloids, tropane alkaloids, steroid alkaloids, polyhydroxy alkaloids), phenolic compounds (e.g. quinines, lignans and flavonoids), terpenoid compounds (e.g. monoterpenoids, iridoids, sesquiterpenoids, diterpenoids and triterpenoids). In addition, secondary metabolites

25 include small molecules (i.e. having a molecular weight of less than 600), such as substituted heterocyclic compounds which may be monocyclic or polycyclic, fused or bridged. Many plant secondary metabolites have value as pharmaceuticals. Plant pharmaceuticals include e.g. taxol, digoxin, colchicines, codeine, morphine, quinine, shikonin, ajmalicine and vinblastine. The definition of "Alkaloids", of which more than

30 12.000 structures have been described already, includes all nitrogen-containing natural products which are not otherwise classified as peptides, non-protein amino acids, amines, cyanogenic glycosides, glucosinolates, cofactors, phytohormones or primary metabolites (such as purine and pyrimidine bases). The "calystegins" constitute a

unique subgroup of the tropane alkaloid class (Goldmann et al. (1990) *Phytochemistry*, 29, 2125). They are characterized by the absence of an N-methyl substituent and a high degree of hydroxylation. Trihydroxylated calystegins are summarized as the calystegin A-group, tetrahydroxylated calystegins as the B-group, and pentahydroxylated derivates form the C-group. Calystegins represent a novel structural class of polyhydroxy alkaloids possessing potent glycosidase inhibitory properties next to longer known classes of the monocyclic pyrrolidones (e.g. dihydroxymethyldihydroxy pyrrolidine) pyrrolines and piperidines (e.g. deoxynojirimycin), and the bicyclic pyrrolizidines (e.g. australine) and indolizidines (e.g. swainsonine and castanospermine). Glycosidase inhibitors are potentially useful as antidiabetic, antiviral, antimetastatic, and immunomodulatory agents.

In another embodiment the invention provides a method for enhancing the production of at least one secondary metabolite in biological cells by transformation of said biological cells with an expression vector comprising an expression cassette further comprising a gene coding for an ABC transporter. Genes useful to be incorporated in an expression cassette for carrying out the present invention include those coding for ATP-binding cassette (ABC) transporters. Genes encoding ABC-transporters can be of any species or origin, including microorganisms, plant and animal (Higgins (1992) *Ann. Rev. Cell Biol.* 8, 67), but are preferably of plant or fungal origin. The ATP-binding cassette (ABC) transporters, also called the "traffic ATPases", comprise a superfamily of membrane proteins that mediate transport and channel functions in prokaryotes and eukaryotes (Higgins, C. F. (1992) *Annu. Rev. Cell Biol.* 8:67-113; Theodoulou F. (2000) *Biochimica et Biophysica Acta* 1465, 79). Typically, an ABC transporter contains two copies each of two structural units: a highly hydrophobic transmembrane domain (TMD), and a peripherally located ATP binding domain or nucleotide binding fold (NBF), which together are often necessary and sufficient to mediate transport. The TMD domains form the pathway via which the substrate crosses the membrane, and in some cases, have been shown to contribute to the substrate specificity. The NBFs are oriented towards the cytoplasmic side of the membrane and couple ATP hydrolysis to transport. Within the NBF is a conserved region of approximately 200 amino acids, consisting of the Walker A and B boxes separated by the ABC signature motif. It is this signature motif which distinguishes ABC transporters from other NTP binding proteins, such as the kinases, which also contain the Walker sequences. Sequence homology

over the whole gene can be negligible between different ABC transporters, but in the conserved areas of the NBF it is typically 30-40% between family members, and this has proved useful in the isolation of ABC genes by approaches such as PCR and hybridisation with degenerate nucleotides (Dudler R. et al (1998) *Methods Enzymol.* 292, 162). A great variety of specific substrates is transported by members of this family of transport proteins, including drugs, anorganic ions, amino acids, proteins, sugars, and polysaccharides. Eukaryotic ABC proteins include: P-glycoproteins, also known as multidrug resistance (MDR) proteins, which are associated with resistance to a wide range of hydrophobic drugs (MDR1; Gottesman, M. M. & Pastan, I. (1993) *Annu. Rev. Biochem.* 62:385-427) or with phosphatidylcholine transport (MDR2; Ruetz, S. & Gros, P. (1994) *Cell* 77:1071-1081); CFTR, the cystic fibrosis transmembrane conductance regulator (Welsh, M. J. & Smith, A. E. (1993) *Cell* 73:1251-1254); TAP proteins, the transporters associated with antigen processing in mammalian cells (Androlewicz, M. J. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:12716-12720); cMOAT/cMRP1, which is associated with transport of glutathione, glucuronide, and sulfate conjugates across the canalicular membrane (Buchler, M. et al. (1996) *J. Biol. Chem.* 271:15091-15098); and STE6, which exports the a-factor mating pheromone of *S. cerevisiae* (Michaelis, S. (1993) *Semin. Cell Biol.* 4:17-27) and PDR5, the pleiotropic drug resistance protein of yeast. Prokaryotic ABC proteins include periplasmic nutrient permeases, such as those responsible for uptake of maltose (MalFGK) and histidine (HisMPQ) in gram-negative bacteria, and toxin exporters such as those required for export of hemolysin (HlyB) and colicin (ColV) from *E. coli*. Sequence comparisons between MRP1 and other ABC transporters reveal two major subgroups among these proteins (Szczypka et al. (1994) *J. Biol. Chem.* 269, 22853). One subgroup comprises MRP1, the *Saccharomyces cerevisiae* cadmium factor (YCF1) gene, the *Leishmania* P-glycoprotein-related molecule (Lei/PgpA) and the CFTRs. The other subgroup comprises the multiple drug resistance proteins (MDRs), MHC transporters and STE6. Homologues of ABC-transporters have been identified in plant species. In *Arabidopsis thaliana*, the glutathione-conjugate transporter (MRP) is located in the vacuolar membrane and is responsible for sequestration of xenobiotics in the central vacuole. An MDR-like gene (atpgp1) has also been identified in *A. thaliana*, which encodes a putative P-glycoprotein homolog. This atpgp1 gene was found to share significant sequence homology and structural organization with human MDR genes. Other MDR homologues have been found in potato and barley. Genes encoding ABC-transporters

of the present invention which may be operably linked with a promoter for expression in a plant species may be derived from a chromosomal gene, cDNA, a synthetic gene, or combinations thereof.

In another embodiment of the invention DNA sequences encoding ABC-transporters
5 are used to enhance the production of at least one secondary metabolite in plant cells comprising the transformation of said plant cells with an expression vector comprising an expression cassette further comprising a gene coding for an ABC-transporter.

By the term "enhanced production" it is meant that the level of one or more metabolites
10 may be enhanced by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or at least 100% relative to the untransformed plant cell which was used to transform with an expression vector comprising an expression cassette further comprising a gene coding for a transporter or an ABC-transporter. An enhanced production of a secondary metabolite can result in a detection of a higher level of secondary metabolites in the extracellular medium of the plant cell culture. Alternatively, a higher level of secondary
15 metabolites can be detected inside the plant cells, for example in the vacuole.

The present invention can be practiced with any plant variety for which cells of the plant can be transformed with an expression cassette of the current invention and for which transformed cells can be cultured *in vitro*. Suspension culture, callus culture, hairy root culture, shoot culture or other conventional plant cell culture methods may
20 be used (as described in: Drugs of Natural Origin, G. Samuelsson, 1999, ISBN 9186274813).

By "plant cells" it is understood any cell which is derived from a plant and can be subsequently propagated as callus, plant cells in suspension, organized tissue and organs (e.g. hairy roots).

25 Tissue cultures derived from the plant tissue of interest can be established. Methods for establishing and maintaining plant tissue cultures are well known in the art (see, e.g. Trigiano R.N. and Gray D.J. (1999), "Plant Tissue Culture Concepts and Laboratory Exercises", ISBN: 0-8493-2029-1; Herman E.B. (2000), "Regeneration and Micropropagation: Techniques, Systems and Media 1997-1999", Agricell Report).

30 Typically, the plant material is surface-sterilized prior to introducing it to the culture medium. Any conventional sterilization technique, such as chlorinated bleach treatment can be used. In addition, antimicrobial agents may be included in the growth medium. Under appropriate conditions plant tissue cells form callus tissue, which may

be grown either as solid tissue on solidified medium or as a cell suspension in a liquid medium.

- A number of suitable culture media for callus induction and subsequent growth on aqueous or solidified media are known. Exemplary media include standard growth media, many of which are commercially available (e.g., Sigma Chemical Co., St. Louis, Mo.). Examples include Schenk-Hildebrandt (SH) medium, Linsmaier-Skoog (LS) medium, Murashige and Skoog (MS) medium, Gamborg's B5 medium, Nitsch & Nitsch medium, White's medium, and other variations and supplements well known to those of skill in the art (see, e.g., Plant Cell Culture, Dixon, ed. IRL Press, Ltd. Oxford (1985) and George et al., Plant Culture Media, Vol 1, Formulations and Uses Exegetics Ltd. Wilts, UK, (1987)). For the growth of conifer cells, particularly suitable media include 1/2 MS, 1/2 L.P., DCR, Woody Plant Medium (WPM), Gamborg's B5 and its modifications, DV (Durzan and Ventimiglia, In Vitro Cell Dev. Biol. 30:219-227 (1994)), SH, and White's medium.
- When secondary metabolites are produced in plant cell culture systems they usually have to be extracted and purified from the isolated plant cell mass which is an expensive process. It is known that plants can be made by means of genetic manipulation to store proteins in seed endosperm, from where they can be more easily extracted. It has also been described that some plant cells can secrete secondary metabolites can be secreted and that said secretion can be enhanced by for example the addition of elicitors (Kneer et al. (1999) J. Exp. Bot. 50, 1553) or by the addition of specific chemicals (Lee et al. (1998) Phytochemistry 49, 2342). It has however never been described that the secretion of secondary metabolites by plant cells can be induced or enhanced by the transformation of at least one specific gene into a plant cell. The present invention provides a solution for this problem by transformation of plant cells, producing secondary metabolites, with an expression cassette comprising a gene encoding an ABC-transporter. Therefore, in another embodiment of the invention a DNA sequence encoding an ABC-transporter can be used to induce or enhance the secretion of at least one secondary metabolite produced in plant cell cultures comprising transforming said plant cells that are producing secondary metabolites, with an expression vector comprising an expression cassette further comprising a gene coding for an ABC-transporter, and selecting transformed plant cells with an induced or enhanced secretion of at least one secondary metabolite. Such transformed plant cells can be subsequently propagated using methods described herein before.

An "enhanced secretion of at least one secondary metabolite" means that there exists already a detectable secretion of the secondary metabolite(s) in the extracellular medium of the plant cell culture and that an increase of the secondary metabolite(s) can be measured by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more than 90% compared to basal secretion by the untransformed plant cell culture. An 'enhanced secretion' does not necessarily mean that there is a higher production, it can also mean that there is exists the same level of production but that the secretion is enhanced. An "induced secretion of at least one secondary metabolite" means that there is no detectable secretion of the secondary metabolite(s) in the extracellular medium of the untransformed plant cell culture but that the detection becomes possible upon carrying out the transformation according to the invention.

Generally secondary metabolites can be measured, intracellularly or in the extracellular space, by methods known in the art. Such methods comprise analysis by thin-layer chromatography, high pressure liquid chromatography, capillary chromatography, (gas chromatographic) mass spectrometric detection, radioimmuno-assay (RIA) and enzyme immuno-assay (ELISA).

In order to make clear what is meant by the word "secretion" in the current invention one has to make a clear distinction between the secretion of proteins which is mediated by an amino-terminal signal peptide and the secretion of secondary metabolites which is independent of an amino-terminal leader sequence. As the term is used herein, secretion means secretion of a secondary metabolite across the plasma membrane or secretion across both the plasma membrane and the cell wall of a plant cell. It should be noted that, in the scientific literature the term "secretion" often is used to indicate secretion into the apoplastic space, i.e., secretion across the plasma membrane but not across the cell wall.

In one aspect of the invention there is no secretion of (a) secondary metabolite(s) into the growth medium. Then, the secretion can be induced by several possibilities: (1) by the transformation of the plant cell with a heterologous gene encoding an ABC-transporter or (2) by the overexpression of a homologous ABC-transporter which expressing is rate-limiting in the plant cell or (3) by the relocalisation of a homologous or heterologous ABC-transporter from a vacuolar localisation towards a membrane localisation. In plants, proteins destined for the vacuole are sorted away from proteins destined for secretion at the trans-Golgi network, a process that requires the presence of positive sorting signals on the vacuolar proteins. Three types of sorting signals have

been described for soluble vacuolar proteins in plants (Matsuoka and Neuhaus (1999) J. Exp. Botany 50, 165). Some proteins contain a cleavable amino-terminal propeptide that functions as a sorting signal while others contain a cleavable carboxy-terminal propeptide. Finally, a minor amount of plant proteins contains an internal vacuolar targeting determinant. According to the invention a homologous or heterologous ABC-transporter that is normally localized in the vacuolar membrane can be engineered by clipping off its vacuolar localisation signal (carboxy-terminal or amino-terminal propeptide) or by deleting its internal vacuolar targeting determinant. If necessary a heterologous or homologous amino-terminal leader sequence is spliced to the gene encoding the homologous or heterologous ABC-transporter in order to provide entry into the secretion system. As a result said engineered ABC-transporter is not directed anymore in the secretion pathway towards its normal vacuolar localisation but is deviated towards the extracellular space. However, due to the hydrophobic transmembrane signal present in ABC-transporters, the ABC-transporter is not secreted into the extracellular medium but remains sequestered into the plasmamembrane of the plant cell. We show in the present invention that the novel intracellular localisation of the ABC-transporter (from the vacuole to the plasma membrane) results in a secretion of the produced secondary metabolites into the medium of the plant cell culture.

In another aspect of the invention there is already an existing but a low level of secretion of (a) secondary metabolite(s) by the plant cell and then the secretion can be enhanced by (1) by the transformation of the plant cell with a heterologous gene encoding an ABC-transporter or (2) by the overexpression of a homologous ABC-transporter which expressing is rate-limiting in the plant cell or (3) by the relocalisation of a homologous or heterologous ABC-transporter from a normal vacuolar localisation towards a membrane localisation.

In yet another aspect of the invention an intermediary product of the secondary metabolite, which causes negative feedback inhibition on an enzymatic reaction step involved in the biosynthesis of said secondary metabolite, can be secreted by (1) by the transformation of the plant cell with a heterologous gene encoding an ABC-transporter or (2) by the overexpression of a homologous ABC-transporter which expressing is rate-limiting in the plant cell or (3) by the relocalisation of a homologous or heterologous ABC-transporter from a vacuolar localisation towards a membrane localisation. The secretion of said intermediary product or an amount produced thereof

reduces the negative feedback inhibition and consequently enhances the production of the secondary metabolite in the plant cell. The enhanced production of said secondary metabolite can be made secreted by the plant cell by the transformation of the already transformed plant cell, with a second expression cassette comprising a gene encoding

5 an ABC transporter, according to the method described above. In this case of secretion, the directed secondary metabolites can be easily isolated from the surrounding medium since they are directed into the extracellular space. Consequently, the breaking up of the cells that is necessary in the case of intracellular production can be omitted.

10 In another embodiment of the invention the production of secondary metabolites can be enhanced by stimulating the transport of secondary metabolites into the vacuole. In plants, the targeting of proteins and compounds into the vacuole is of particular interest (especially from the point of view of application) because the vacuole is the largest storage compartment in the cell for reserve substances, detoxification products and

15 defence substances. The most important storage takes place in vacuoles in plant organs such as tubers, bulbs, roots and stems. Similar considerations also apply to substances that can be used in the control of pests or diseases, especially when those substances prove to be toxic to the plant itself. Indeed, in certain cases the vacuole also serves as a detoxification organelle by, for example, storing the detoxification

20 products synthesised by the plant. According to the present invention secondary metabolites can also be made secreted into the vacuole (1) by the transformation of a plant cell with a heterologous gene encoding an ABC-transporter or (2) by the overexpression of a homologous ABC-transporter which expressing is rate-limiting in the plant cell or (3) by the relocalisation of a homologous or heterologous ABC-

25 transporter from a normally localised plasmamembrane localisation towards a vacuolar localisation. To perform said relocalisation it is necessary to modify the gene encoding an ABC-transporter by genetically fusing it to an amino-terminal or carboxy-terminal vacuolar localisation signal or by the genetic modification through the introduction of an existing internal vacuolar localisation signal. US patent 6,054,637 provides detailed

30 information of genetic modification of genes through the addition or clipping off plant vacuolar localisation signals. We observe that the secretion or targeting of the produced secondary metabolites into the vacuole reduces the toxicity to the plant cell. In yet another embodiment of the invention an intermediary product of the secondary metabolite, which causes negative feedback inhibition on an enzymatic reaction step

- involved in the biosynthesis of said secondary metabolite, can be made sequestered into the vacuole by (1) the transformation of the plant cell with a heterologous gene encoding an ABC-transporter or by (2) the overexpression of a homologous ABC-transporter which expressing is rate-limiting in the plant cell or (3) by the relocation 5 of a homologous or heterologous ABC-transporter from a normal membrane localisation towards a vacuolar localisation. The import of said intermediary product, or an amount produced thereof, into the vacuole reduces the negative feedback inhibition of the enzymatic reaction which occurs outside the vacuole and consequently enhances the production of the secondary metabolite in the plant cell.
- 10 In another embodiment the current invention can be combined with other known methods to enhance the production and/or the secretion of secondary metabolites in plant cell cultures such as (1) by improvement of the plant cell culture conditions, (2) by the transformation of the plant cells with a transcription factor capable of upregulating genes involved in the pathway of secondary metabolite formation, (3) by 15 the addition of specific elicitors to the plant cell culture, and 4) by the induction of organogenesis.

In another embodiment of the invention DNA sequences encoding ABC-transporters are used to enhance the production of at least one secondary metabolite in plants comprising the transformation of said plants with an expression vector comprising an 20 expression cassette further comprising a gene coding for an ABC-transporter.

By the term "to enhance the production" it is meant that the level of one or more metabolites may be enhanced by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or at least 100% relative to the untransformed plant which was used to transform with an expression vector comprising an expression cassette further comprising a gene 25 coding for a transporter or an ABC-transporter. An enhanced production of a secondary metabolite can result in a detection of a higher level of secondary metabolites in the plant, for example in the vacuole. In another embodiment the enhanced production of at least one secondary metabolite leads to an enhanced secretion. In yet another embodiment the same production of at least one secondary 30 metabolite occurs in the transformed plant but an enhanced secretion of at least one secondary metabolite occurs by said transformed plant. Secondary metabolites can for example be efficiently produced by continuous secretion from the roots of hydroponically grown plants. This process of secretion is also been termed 'rhizosecretion'.

The term "plant" as used herein refers to vascular plants (e.g. gymnosperms and angiosperms). The method comprises transforming a plant cell with an expression cassette of the present invention and regenerating such plant cell into a transgenic plant. Such plants can be propagated vegetatively or reproductively. The transforming 5 step may be carried out by any suitable means, including by *Agrobacterium*-mediated transformation and non-*Agrobacterium*-mediated transformation, as discussed in detail below. Plants can be regenerated from the transformed cell (or cells) by techniques known to those skilled in the art. Where chimeric plants are produced by the process, 10 plants in which all cells are transformed may be regenerated from chimeric plants having transformed germ cells, as is known in the art. Methods that can be used to transform plant cells or tissue with expression vectors of the present invention include both *Agrobacterium* and non-*Agrobacterium* vectors. *Agrobacterium*-mediated gene transfer exploits the natural ability of *Agrobacterium tumefaciens* to transfer DNA into plant chromosomes and is described in detail in Gheysen, G., Angenon, G. and Van 15 Montagu, M. 1998. *Agrobacterium*-mediated plant transformation: a scientifically intriguing story with significant applications. In K. Lindsey (Ed.), *Transgenic Plant Research*. Harwood Academic Publishers, Amsterdam, pp. 1-33 and in Stafford, H.A. (2000) *Botanical Review* 66: 99-118. A second group of transformation methods is the 20 non-*Agrobacterium* mediated transformation and these methods are known as direct gene transfer methods. An overview is brought by Barcelo, P. and Lazzeri, P.A. (1998) *Direct gene transfer: chemical, electrical and physical methods*. In K. Lindsey (Ed.), *Transgenic Plant Research*, Harwood Academic Publishers, Amsterdam, pp.35-55. Hairy root cultures can be obtained by transformation with virulent strains of 25 *Agrobacterium rhizogenes*, and they can produce high contents of secondary metabolites characteristic to the mother plant. Protocols used for establishing of hairy root cultures vary, as well as the susceptibility of plant species to infection by *Agrobacterium* (Toivunen L. (1993) *Biotechnol. Prog.* 9, 12; Vanhala L. et al. (1995) *Plant Cell Rep.* 14, 236). It is known that the *Agrobacterium* strain used for transformation has a great influence on root morphology and the degree of secondary 30 metabolite accumulation in hairy root cultures. It is possible that by systematic clone selection e.g. via protoplasts, to find high yielding, stable, and from single cell derived-hairy root clones. This is possible because the hairy root cultures possess a great somaclonal variation. Another possibility of transformation is the use of viral vectors (Turpen TH (1999) *Philos Trans R Soc Lond B Biol Sci* 354(1383): 665-73).

- Any plant tissue or plant cells capable of subsequent clonal propagation, whether by organogenesis or embryogenesis, may be transformed with an expression vector of the present invention. The term 'organogenesis' means a process by which shoots and roots are developed sequentially from meristematic centers; the term
5 'embryogenesis' means a process by which shoots and roots develop together in a concerted fashion (not sequentially), whether from somatic cells or gametes. The particular tissue chosen will vary depending on the clonal propagation systems available for, and best suited to, the particular species being transformed. Exemplary tissue targets include protoplasts, leaf disks, pollen, embryos, cotyledons, hypocotyls,
10 megagametophytes, callus tissue, existing meristematic tissue (e.g. apical meristems, axillary buds, and root meristems), and induced meristem tissue (e.g., cotyledon meristem and hypocotyls meristem).
- These plants may include, but not limited to, plants or plant cells of agronomically important crops, such as tomato, tobacco, diverse herbs such as oregano, basilicum
15 and mint. It may also be applied to plants that produce valuable compounds, e.g. useful as for instance pharmaceuticals, as ajmalicine, vinblastine, vincristine, ajmaline, rserpine, rescinnamine, camptothecine, ellipticine, quinine, and quinidien, taxol, morphine, scopolamine, atropine, cocaine, sanguinarine, codeine, genistein, daidzein, digoxin, colchicines, calystegins or as food additives such as anthocyanins, vanillin;
20 including but not limited to the classes of compounds mentioned above. Examples of such plants include, but not limited to, *Papaver spp.*, *Rauvolfia spp.*, *Taxus spp.*, *Cinchona spp.*, *Eschscholtzia californica*, *Camptotheca acuminata*, *Hyoscyamus spp.*, *Berberis spp.*, *Coptis spp.*, *Datura spp.*, *Atropa spp.*, *Thalictrum spp.*, *Peganum spp.*
- 25 In another embodiment the invention provides an isolated polypeptide selected from the groups consisting of (a) an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO: 1; (b) an isolated polypeptide comprising a polypeptide sequence having a least 83 % identity to the polypeptide sequence of SEQ ID NO: 2; (c) fragments and variants of such polypeptides in (a) to (b) that induce or
30 enhance the production or the secretion of at least one secondary metabolite in plants or plant cells.

In another embodiment the invention provides an isolated polynucleotide selected from the groups consisting of (a) an isolated polynucleotide comprising a polynucleotide

- sequence of SEQ ID NO: 1; (b) an isolated polynucleotide comprising a polynucleotide sequence having at least 91% identity to SEQ ID NO: 1; (c) fragments and variants of such polynucleotides in (a) to (b) that induce or enhance the production or the secretion of at least one secondary metabolite in plants or plant cells.
- 5 As used herein, the words "polynucleotide" may be interpreted to mean the DNA and cDNA sequence as detailed by Yoshikai et al. (1990) *Gene* 87:257, with or without a promoter DNA sequence as described by Salbaum et al. (1988) *EMBO J.* 7(9):2807.
- As used herein, "fragment" refers to a polypeptide or polynucleotide of at least about 9 amino acids or 27 base pairs, typically 50 to 75, or more amino acids or base pairs,
- 10 wherein the polypeptide contains an amino acid core sequence. If desired, the fragment may be fused at either terminus to additional amino acids or base pairs, which may number from 1 to 20, typically 50 to 100, but up to 250 to 500 or more. A "functional fragment" means a polypeptide fragment possessing the biological property of that induce or enhance the production or the secretion of at least one secondary
- 15 metabolite in plants or plant cells. The terms 'identical' or percent 'identity' in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e. 70% identity over a specified region), when compared and aligned for maximum correspondence over a comparison
- 20 window, or designated region as measured using sequence comparison algorithms or by manual alignment and visual inspection. Preferably, the identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides or even more in length. Examples of useful algorithms are PILEUP (Higgins & Sharp, CABIOS 5:151 (1989), BLAST and
- 25 BLAST 2.0 (Altschul et al. *J. Mol. Biol.* 215: 403 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>).

Examples

- 30 The recombinant DNA and molecular cloning techniques applied in the below examples are all standard methods well known in the art and are e.g. described by Sambrook et al. (1989) *Molecular cloning: A laboratory manual*, second edition, Cold Spring Harbor Laboratory Press. Methods for yeast culture and manipulation applied in the below examples are all standard methods well known in the art and are described

e.g. in Guthrie and Fink (1991) Guide to yeast genetics and molecular biology, academic Press, Inc., New York. Methods for tobacco cell culture and manipulation applied in the below examples are methods described in or derived from methods described in Nagata et al. (1992) Int. Rev. Cytol. 132, 1.

5

EXAMPLE 1: Identification of yeast multidrug resistance transporters specific for tropane (Tas) and nicotine-type alkaloids (NAs)

In the yeast *Saccharomyces cerevisiae*, a complex pleiotropic drug resistance (PDR) network of genes involved in multidrug resistance is composed of the transcriptional regulators Pdr1p and Pdr3p, which activate expression of the ATP-binding cassette (ABC) transporter-encoding genes *PDR5*, *SNQ2*, *YOR1*, as well as other not yet identified genes. To assess yeast sensitivity towards tropane alkaloids (Tas) and nicotine alkaloids (Nas) and identify yeast ABC transporters with specificity for TAs and NAs, we have screened isogenic yeast strains deleted of the ABC transporters *YOR1*, *SNQ2*, *PDR5*, *PDR10*, *PDR11* or *YCF1* for tolerance to the toxic compounds hyoscyamine, scopolamine and nicotine. The isogenic yeast strains derived from the US50-18C genotype were constructed and described in Decottignies et al. (*J. Biol. Chem.* (1998) 273, 12612). The yeast strains derived from the BY4741 genotype are obtained from the EUROSCARF collection (Frankfurt, Germany). All strains are listed in Table 1.

Table 1. Yeast strains used	
Strain	Genotype
US50-18C	<i>Matα pdr1-3 ura3 his1</i>
AD1	US50-18C <i>yor1::hisG</i>
AD2	US50-18C <i>snq2::hisG</i>
AD3	US50-18C <i>pdr5::hisG</i>
AD4	US50-18C <i>pdr10::hisG</i>
AD5	US50-18C <i>pdr11::hisG</i>
BY4741	<i>Matα his3Δ1 leu2Δ0 met15Δ0 ura3Δ0</i>
Y02409	BY4741 <i>pdr5::kanMX4</i>
Y03951	BY4741 <i>snq2::kanMX4</i>
Y04069	BY4741 <i>ycf1::kanMX4</i>
Y05933	BY4741 <i>yor1::kanMX4</i>

Alkaloid tolerance was assessed by controlling growth performance on rich medium (YPD) that contained different concentrations of TAs or NAs. To this end the different strains were grown to saturation (48h) in liquid YPD. Cultures were diluted 10-, 100- and 1000-fold, and volumes of about 3 µl were dropped with a stainless steel replicator on YPD plates containing 2% Bacto Agar with the toxic compounds. Rich medium contains 1% yeast extract, 2% Bacto Peptone and 2% glucose. Filter-sterilized water solutions of hyoscyamine, scopolamine and nicotine were added after autoclaving. Growth was evaluated after two days incubation at 28°C. We observed that wild type yeast (i.e. not deleted for one of the ABC transporters) can tolerate hyoscyamine, scopolamine and nicotine to levels of 50 mM, 100 mM, and 15 mM respectively. Gradually increasing alkaloid levels in the medium caused growth retardation and was finally lethal. All isogenic strains except the *pdr5* mutant strain showed identical alkaloid sensitivity. The above-mentioned alkaloid concentrations were lethal for the strain deleted for the *PDR5* gene. This indicates that Pdr5p shows substrate specificity for TAs and NAs and is the only known ABC transporter involved in TA or NA transport in yeast cells. Previously other plant secondary metabolites such as indole alkaloids (e.g. vinblastine and vincristine), taxol and flavonoids were also shown to be substrates for Pdr5p mediated multidrug transport (Kolaczkowski et al. (1996) J. Biol. Chem. 271, 31543 and Kolaczkowski et al. (1998) Microb. Drug Resist. 4, 143).

EXAMPLE 2: Assessment of toxicity of TAs and NAs to tobacco BY-2 suspension cultured cells

Suspension cultured tobacco cells, *Nicotiana tabacum* L. cv Bright Yellow 2 were grown in the dark at 26°C on a rotary shaker (130 rpm) in MSST, a modified Murashige-Skoog basal medium supplemented with 1.5 mM KH₂PO₄, 3 µM thiamine, 0.55 mM inositol, 87 mM sucrose and 1 µM 2,4D. Cells are subcultured every 7 days by transferring 0.5 ml into 50 ml of fresh medium in 250-ml flasks.

Toxicity of TAs and NAs to tobacco BY-2 cells was assessed in two ways. In the first method growth performance on MSST medium containing different concentrations of TAs or NAs was controlled. To this end a fresh BY-2 cell culture was started and after 3 days culture volumes of about 300 µl were dropped on MSST plates containing 0.65% Bacto Agar and the toxic alkaloids. Filter-sterilised water solutions of hyoscyamine and nicotine were added after autoclaving. Growth was evaluated after

15 days incubation at 26°C. Wildtype BY-2 cells (i.e. not transgenic) can tolerate hyoscyamine and nicotine without severe growth problems to levels of 30 mM and 3 mM respectively. Gradually increasing alkaloid levels in the medium caused growth retardation and finally was lethal. In the second method toxicity was evaluated by
5 measuring cell death after incubation in the presence of increasing levels of alkaloids. Cell death was scored by the Evans blue method (Turner and Novacky (1974) *Phytopathol.* 64, 885). To this end a fresh BY-2 cell culture was started and after 3 days 5 ml of this culture was transferred to one well of a 6-well plate (Falcon 353046).
10 1 ml of fresh MSST was added and the desired toxic compound in a volume of 650 µl in 0.1M potassium phosphate buffer at pH 5.8. Cells were then further incubated on the rotary shaker and 1-ml samples were taken after 0, 6 and 24 hours. We spinned the cells down at 6000 rpm for 3 minutes, removed the supernatant, added 1 ml of 0.1% Evans blue in MSST medium and incubated for 15 minutes at room temperature on a rotary wheel. Afterwards we spinned the cells down again and washed 5 times
15 with fresh MSST medium till all the blue color was gone from the supernatant. Dye bound to dead cells was solubilised by incubation in 1 ml of 50% methanol, 1% SDS for 30 minutes at 50°C. We spinned the cells down again (now at 14000 rpm for three minutes) and quantified cell death by measuring OD₆₀₀ of the supernatant. Cell death is expressed as fold increase in Evans blue staining compared to the control cells. In
20 this assay tobacco BY-2 cells are found sensitive to all the compounds tested. Hyoscyamine and nicotine cause the death of all suspension cultured tobacco cells within 24 hours of incubation at levels of 50 mM and 20 mM respectively. This indicates that the metabolites that plants produce inside the cells can be toxic for themselves and also that this toxicity can result in slow growth of plant cells producing
25 secondary metabolites. Furthermore these results provided us with useful assay systems for evaluating the activity of ABC transporters from different organisms such as yeast, plants and animals in tobacco cell suspension cultures.

EXAMPLE 3: Expression of *PDR5* in tobacco BY-2 suspension cultured cells

30 3.1 Cloning of *PDR5*

The *PDR5* gene was cloned by the PCR method with the *Pful* polymerase. To this end oligonucleotides were designed with 5'-terminal *attB* sequences that amplify the entire open reading frame of the *PDR5* gene (4536 nt) as a PCR product that is an efficient substrate for recombination with the Gateway™ system (InVitroGen). Gateway

(Invitrogen) technology provides an alternative rapid method for cloning a sequence into a multiple expression system. The advantage of the Gateway cloning is that fragments present as Entry clones can be subcloned into different Destination vectors in a short time. This technology was used to construct a set of versatile vectors for

5 Agrobacterium -based plant transformation. Our intention was to develop vectors for wide range plant gene analysis. The Gateway-compatible binary vector pPZP200 is the backbone of our constructs (Hajdukiewicz et al. *Plant Molecular Biology* 25, 989-994, 1994). This binary vector is relatively small in size, contains two origins of replication in *E. coli* or in *Agrobacterum* and posses streptomycin and/or spectinomycin

10 for plasmid selection. Three plant selectable marker genes; kanamycin, hygromycin and bar (most frequently used markers in plant transformation) have been used for all constructs. All selectable markers are in a cassette containing nos (nopaline synthase) promoter and nos terminator. These genes were cloned toward the left border of the T-DNA. For construction of all Gateway clones we have used the rfA conversion

15 cassette.

The oligonucleotides used for *PDR5* gene cloning, are 5'-AAAAGCAGGCTACCATGCCCGAGGCCAAGCTAACATA-3' as the forward primer and 5'- AGAAAGCTGGTCCATCTTGGTAAGTTCTTTCTTAACC-3' as the reverse primer, respectively. As a template genomic DNA prepared from the yeast strains US50-18C or W303 was used. First the PCR fragments were introduced in the Donor Vector pDONR201 (InVitroGen) via the BP reaction to generate the Entry Clone. Then the *PDR5* gene was transferred to the Destination Vector pK7WGD2 (Fig. 1) via the LR reaction, where the gene is under control of the CaMV 35S promoter. The T-DNA of the pK7WGD2 binary vector also bears the kanamycin resistance gene (NPTII) under the control of the pnos promoter as selectable marker for plant transformation and the gene encoding the green fluorescent protein (GFP) under the control of the proID promoter for visual selection of transgenic plant cell lines. The resulting binary plasmids were designated pK7WGD2-ScPDR5-US50 or pK7WGD2-ScPDR5-W303 depending on the yeast genotype from which the gene is isolated. Also the GUS gene was introduced in the pK7WGD2 vector and the resulting binary vector pK7WGD2-GUS served as a control for the experiments described in the examples below.

3.2 Transformation of tobacco BY-2 suspension cultured cells

Plant cell transformations were carried out by applying the ternary vector system (van der Fits et al. (2000) *Plant Mol. Biol.* 43, 495). The plasmid pBBR1MCS-5.virGN54D is

used as a ternary vector. The binary plasmid was introduced into *Agrobacterium tumefaciens* strain LBA4404 already bearing the ternary plasmid by electro-transformation.

Agrobacterium tumefaciens strains were grown for three days at 28°C on solid LC medium containing 20 µg/ml rifampicin, 40 µg/ml geneticin, 100 µg/ml spectinomycin and 300 µg/ml streptomycin. LC medium contains 1% Bacto Trypton, 0.5% Bacto yeast extract and 0.8% NaCl. From these bacteria a 5-ml liquid culture was grown in LC medium for 48 hours. *N. tabacum* BY-2 cells were grown in MSST medium as described in example 2. For transformation 3 days old cell cultures were used. For cocultivation 4 ml of BY-2 cells was transferred to the corner of a petridish (Ø 80 mm) and 300 µl of the *A. tumefaciens* culture was added. Dishes were taped with respiratory tape and incubated for 3 days at 26°C in the dark. After 3 days the cocultivation mixture was transferred into 20 ml of fresh MSST medium 50 µg/ml kanamycin-B, 500µg/ml carbenicillin and 250 µg/ml vancomycin in 100-ml flasks and further incubated as described in example 2. After one week 4 ml of this cell suspension culture was subcultured in 40 ml of fresh MSST medium with 10 µg/ml of the kanamycin analogue G-418 (geneticin), 500µg/ml carbenicillin and 250 µg/ml vancomycin and grown further till it reached maximal density (similar to stationary, 1-week-old culture) which took two to three weeks, depending on the efficiency of the transformation event. After two additional 1 ml transfer cycles in medium containing 50 µg/ml kanamycin-B, 500µg/ml carbenicillin and 250 µg/ml vancomycin cells were further propagated in an antibiotic-free MSST medium as described in example 2. Elimination of agrobacteria was verified and efficient transgene expression was scored *in vivo* by observing GFP fluorescence with a fluorescence microscope equipped with HQ-GFP band-pass filters for an excitation at 470 and emission at 525 nm.

3.3 Effect of heterologous PDR5 expression in BY-2 suspension cultured cells on alkaloid tolerance

In recombinant BY-2 cells transformed with the PDR5 expression cassettes (from both yeast genotypes), correct PDR5 expression is tested by northern blot analysis using a PDR5 specific DNA probe and by western blot analysis using a rabbit polyclonal anti-Pdr5p antibody (Decottignies et al. (1999) J. Biol. Chem. 274, 37139). In both lines PDR5 is efficiently expressed both on the RNA and protein level. Fractionation also shows that the Pdr5 protein is correctly targeted to the plasma membrane. Tolerance of the transformed BY-2 suspension cultures to hyoscyamine and nicotine was

assessed by the two assays described in example 2. As can be deduced from the growth performance assay, BY-2 cell lines expressing the different yeast Pdr5 transporters displayed to varying extents an increased tolerance to both alkaloids as compared to the control GUS-expressing lines. Lines expressing the PDR5 transporter from yeast genotype W303 showed the highest alkaloid tolerance, in particular towards hyoscyamine. In the cell death experiment hyoscyamine was added to a final concentration of 30 mM. Transgene BY-2 cells expressing the Pdr5p from yeast strain W303 again showed the highest tolerance to this tropane alkaloid (Fig. 2). Fold increase in cell death lowered with ca. 35% in the W303 lines whereas US50 lines had a 15% decrease in hyoscyamine induced cell death.

3.4 Effect of heterologous PDR5 expression in BY-2 suspension cultured cells on nicotinic alkaloid production

For the analysis of nicotinic alkaloid accumulation 6-days old recombinant BY-2 cell cultures (BY-2 transformed with pK7WGD2-ScPDR5-US50 or pK7WGD2-ScPDR5-W303 or pK7WGD2-GUS) were washed and diluted ten-fold with fresh hormone free MSST medium. After a recuperation period of 12 hours, the cultures were treated with methyl jasmonate (MeJA). MeJA was dissolved in dimethyl sulfoxide (DMSO) and added to the culture medium at a final concentration of 50 µM. As a control, cells treated with an equivalent amount of DMSO were included. For alkaloid analysis, three replicate shake flasks with a volume of 20 ml were processed. After vacuum-filtering through Miracloth, cells and medium were separated from each other for intracellular and extracellular alkaloid analysis respectively. The filtered cell mass was transferred to a test tube, frozen and lyophilized (50 mbar, approx. 48 hours). Lyophilised cell samples were extracted for GC-MS analysis by a modified method described by Furuya et al. (1971, Phytochemistry, 10, 1529). Cells were weighed and 25 µg 5- α -cholestane was added as internal standard. The samples are made alkaline with ammonia (10 % (v/v), 1 ml) and water (2 ml) is added. Alkaloids were extracted by vortexing with 2 ml of dichloromethane. After 30 min the samples were centrifuged (2000 rpm, 10 min) and the lower organic layer was separated and transferred into glass vials. After evaporation to dryness 25 µl of dichloromethane was added and the samples were silylated with N-methyl-N-(trimethylsilyl)trifluoroacetamide (Pierce, Rockford, USA) for 20 min at 120 °C prior to GC-MS analysis. For alkaloid determination in the medium, 20 ml of the filtered medium was made alkaline with ammonia (10% v/v) to reach pH 9. Internal standards were added (5- α -cholestane and

cotinine). Subsequently this solution was extracted twice with dichloromethane (1:1) and evaporated to dryness. The column was rinsed twice with 1 ml of dichloromethane and the extract was transferred into glass vials. We further proceeded as described above for the cell extract.

5

Table 2. Alkaloid accumulation in transformed BY-2 cells^a

BY-2 Strain	Nicotine ^b		Anatabine ^b		
	Medium	Cells	Medium	Cells	% in medium
GUS	0	2.00	0.18	157	0.1
ScPDR5-US50	0	0.88	7.40	207	3.6
ScPDR5-W303	0	2.03	5.12	74	6.9

^a Measured 72 hours after elicitation with 50 µM methyl jasmonate. Results are the mean of three independent experiments

^b Indicated in µg/flask, with 20-ml BY-2 culture per flask

15

In jasmonate elicited BY-2 cells the alkaloids detected after 72 hours are nicotine, anabasine, anatabine and anatalline. No alkaloids are detected in DMSO-treated samples, neither in the cells nor in the medium. The results for nicotine and anatabine are shown in Table 2. Of all alkaloids that are produced by elicited BY-2 cells only anatabine is found in the medium. Although only trace amounts of anatabine can be detected extracellularly, comparison of anatabine levels in the different BY-2 cell lines after 72 hours of MeJA treatment clearly shows an enhancement of anatabine export in cell lines transformed with the *PDR5* genes.

25 EXAMPLE 4: Expression of vacuole targeted PDR5 in tobacco BY-2 suspension cultured cells

4.1 Construction and cloning of recombinant PDR5

To target the yeast PDR5 protein to plant vacuolar membranes two strategies are followed. In the first the N-terminal signal peptide and pro-peptide from sweet potato (MKAFTLALFLALSLYLLPNPAHSRFNPIRLPTTHEPA, Matsuoka and Nakamura (1991) Proc. Natl. Acad. Sci. USA 88, 834) are fused at the N-terminus of the Pdr5 protein. The resulting recombinant open reading frame is designated ScNVacPDR5. In the second approach the C-terminal amino acids of the tobacco chitinase A (DLLGNGLLVDTM, Neuhaus et al. (1991) Proc. Natl. Acad. Sci. USA 88, 10362) are

added at the C-terminus of the Pdr5 protein. The resulting recombinant open reading frame is designated ScPDR5CVac. Both recombinant genes are put under the control of the CaMV35S promoter and cloned in the binary vector bearing the HYG and GFP genes as described in example 3.1. The resulting binary plasmids are designated pH-
5 ScNVacPDR5-GFP and pH-ScPDR5CVac-GFP, respectively.

4.2 Effect of recombinant PDR5 expression in BY-2 suspension cultured cells on alkaloid tolerance and nicotine production

BY-2 suspension cultured cells are transformed as described in example 3.2 and
5 transgene calli of both ScNVacPDR5 or ScPDR5CVac transformed cells and highly
10 expressing GFP are selected as described in example 3.3. Control of expression of
recombinant PDR5 is performed as described in example 3.3 by northern and western
blot analysis. Fractionation shows that in both types of transgene lines (NVac or CVac)
the Pdr5 protein is targeted to the vacuolar membrane.

To assess tolerance to nicotine and hyoscyamine in transgenic cell lines the same
15 assays as described in example 3.3 are used here to evaluate the functionality of
vacuole targeted Pdr5p. The effect of the vacuolar expression of *PDR5* on nicotine
production in BY-2 cells is evaluated as described in example 3.4.

EXAMPLE 5: Expression of plant PDR orthologues in tobacco BY-2 suspension
20 cultured cells

5.1. Cloning of AtPDR1

The ABC protein super-family is the largest protein family known and most are
membrane proteins active in the transport of a broad range of substances across the
membranes. Also in *Arabidopsis* this superfamily is large and diverse (129 ORFs) and
25 a complete inventory has been described by Sanchez-Fernandez et al. (J. Biol. Chem.
(2001), 276, 30231). One of the subfamilies of full-length ABC transporters in
Arabidopsis consists of the PDRs (13 ORFs) of which yeast *PDR5* is the prototype. At
least eight of the *PDR5*-like ORFs in *Arabidopsis* are transcriptionally active and have
been isolated as ESTs (Sanchez-Fernandez et al. (2001), J. Biol. Chem., 276, 30231).
30 Amongst these is one of the closest *Arabidopsis* PDR5-orthologues, namely the
AtPDR1 gene (At3g16340). A cDNA clone of the *AtPDR1* gene is isolated as
described for the yeast *PDR5* gene in example 3. To this end the following
oligonucleotides were designed: 5'-
AAAAAGCAGGCTACCATGGAGACGTTATCGAGAA-3' as the forward primer and 5'-
AAAAAGCAGGCTACCATGGAGACGTTATCGAGAA-3'

AGAAAGCTGGGTCTATCGTTGGAAGTTGAGC-3' as the reverse primer, respectively. As a template we used cDNA prepared from *Arabidopsis* hypocotyls.

5.2 Cloning of HmPDR1

The biosynthesis of tropane alkaloids such as hyoscyamine and scopolamine in plants of the Solanaceae is very tissue-specific and occurs only in the roots. Later on the alkaloids are transported to the aerial parts, especially the leaves, where they are finally accumulated. In hairy roots however this translocation cannot occur and part of the produced alkaloids are released in the medium. This release can be stimulated by the addition of millimolar amounts of CdCl₂ to the medium (Furze et al. (1991) Plant Cell Rep. 10, 111 and Pitta-Alvarez et al. (2000) Enzyme. Microb. Technol. 26, 252). This indicates the existence of active detoxifying mechanisms against cadmium in which also the tropane alkaloids would be involved. We applied this knowledge to isolate an alkaloid specific PDR-like gene from *Hyoscyamus muticus* hairy roots.

A cDNA clone of a PDR-like gene is isolated from *H. muticus* and is designated HmPDR1. To this end total RNA was prepared from hairy roots of the *H. muticus* KB7 line (Jouhikainen et al. (1999) Planta 208, 545) treated for 30 hours with 1 mM CdCl₂ and was reverse transcribed with the Superscript RTII reverse transcriptase. A nested PCR was subsequently carried out with the *Taq* DNA polymerase using the DNA-RNA hybrid as the template and two sets of degenerate primers designed from highly conserved amino acid sequences in the nucleotide binding folds of known yeast and plant PDR proteins (see Table 3). This PCR yields two fragments derived from the two nucleotide-binding folds which are naturally present in the general tandem repeat structure of ABC proteins. Using specific primers and RT-PCR, 5'RACE and 3'RACE techniques we cloned a full-length cDNA clone, which is designated HmPDR1. The nucleotide sequence of the HmPDR1 cDNA clone is depicted in SEQ ID NO: 1, the amino acid sequence of the HmPDR1 protein is depicted in SEQ ID NO: 2.

Table 3. Degenerate primers used for HmPDR1 cDNA cloning

Primer	Sequence
ALGG39	5'-CCIRGYKCIGGIAARACNAC-3'
ALGG40	5'-ACICKYTTYTTGNCCNCC-3'
ALGG41	5'-TCNARNCC-3'
ALGG42	5'-GGIGTIYTACIGCNYTNATGGG-3'
ALGG43	5'-TCNARCATCCAIGTIGCNGGRTT-3'
ALGG44	5'-CKCCARTA-3'

To confirm the postulated relationship between the expression of ABC transporter genes and the CdCl₂ induced release of alkaloids we performed an expression analysis of the HmPDR1 gene in CdCl₂ treated *Hyoscyamus* hairy roots (Fig. 3).

5 Quantitative RT-PCR clearly showed that HmPDR1 is upregulated by CdCl₂ elicitation.

5.3 Effect of heterologous AtPDR1 expression in yeast cells on alkaloid tolerance

The *AtPDR1* gene was subcloned in a yeast expression vector (YCp50) between the 5' and 3' regulatory sequences of the yeast *PDR5* gene. This plasmid was then introduced in the yeast AD3 strain (the *pdr5* mutant, see example 1). To analyze the

10 substrate specificity of this plant PDR gene we controlled growth performance of the transformed yeast strains on YPD plates containing the different TAs and NAs as described in example 1. We have shown that the *PDR1* gene of *A. thaliana* was able to restore the growth of the *pdr5* mutant strain on hyoscyamine and nicotine.

5.4 Effect of heterologous AtPDR1 expression in BY-2 suspension cultured cells on

15 alkaloid tolerance

The *AtPDR1* gene was transferred to the binary vector pK7WGD2 as described in example 3.1. BY-2 suspension cultured cells were transformed as described in example 3.2. Control of expression of *AtPDR1* is performed by northern blot analysis using a specific DNA probe. To assess tolerance to nicotine and hyoscyamine in

20 transgenic cell lines the same assays as described in example 3.3 were performed in order to evaluate the functionality of AtPDR1p. Transgenic BY-2 cells showed enhanced tolerance to alkaloids as compared to the control GUS expressing line. However, not to the extent of the ScPDR5-W303 expressing line but comparable to the tolerance levels obtained in the ScPDR5-US50 line.

25

5.5 Effect of AtPDR1 expression in BY-2 suspension cultured cells on nicotinic alkaloid production

For the analysis of nicotinic alkaloid accumulation 6-days old recombinant BY-2 cell cultures (pK7WGD2-AtPDR1 en pK7WGD2-GUS) are washed and diluted ten-fold with
30 fresh hormone free MSST medium. After a recuperation period of 12 hours, the cells are treated with methyl jasmonate (MeJA). MeJA is dissolved in dimethyl sulfoxide (DMSO) and added to the culture medium at a final concentration of 50 µM. As a control, cells treated with an equivalent amount of DMSO are included. For alkaloid analysis the same process is followed as in example 3.4.

Claims

1. Use of an expression cassette comprising a gene encoding an ABC-transporter to induce or to enhance the production or the secretion of at least one secondary metabolite by plant cells comprising:
 - 5 - transforming said plant cells with an expression vector comprising said expression cassette,
 - selecting transformed plant cells with an induced or enhanced production or secretion of at least one secondary metabolite, and
 - propagating such selected transformed cells.
- 10 2. Use of an expression cassette according to claim 1 wherein the induction or enhancement of the production of at least one secondary metabolite by plant cells results from enhancing the transport of said metabolite into the vacuole.
- 15 3. Use of an expression cassette comprising a gene encoding an ABC-transporter to stimulate the production of secondary metabolites by plants comprising:
 - transforming said plants with an expression vector comprising said expression cassette,
 - selecting transformed plants with an enhanced production, and
 - propagating such selected transformed plants.
4. Use according to claims 1-3 wherein said secondary metabolites are alkaloids.
- 20 5. Use according to claims 1-3 wherein said ABC-transporters are derived from plants, fungal or mammalian cells.
6. A transgenic plant cell culture, with an enhanced production or secretion of an at least one secondary metabolite, transformed with an expression vector comprising an expression cassette according to claim 1.
- 25 7. A transgenic plant, the cells, seeds and progeny thereof which have an enhanced production or secretion of an at least one secondary metabolite, transformed with an expression vector comprising an expression cassette according to claim 3.
8. A transgenic plant cell culture according to claim 6 further characterized in (1) having an increased vacuolar localisation of said secondary metabolite, or (2)
30 having a secretion or an increased secretion of said secondary metabolite.
9. A transgenic plant according to claim 7 further characterized in having an increased vacuoiar localisation of said secondary metabolite.

10. An isolated polypeptide selected from the groups consisting of:
- a. an isolated polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO: 1;
 - b. an isolated polypeptide comprising a polypeptide sequence having at least 83 % identity to the polypeptide sequence of SEQ ID NO: 2;
 - c. fragments and variants of such polypeptides in (a) to (b) that induce or enhance the production or the secretion of at least one secondary metabolite in plants or plant cells.
11. An isolated polynucleotide selected from the groups consisting of:
- a. an isolated polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 1;
 - b. an isolated polynucleotide comprising a polynucleotide sequence having at least 91% identity to SEQ ID NO: 1;
 - c. fragments and variants of such polynucleotides in (a) to (b) that induce or enhance the production or the secretion of at least one secondary metabolite in plants or plant cells.

20

25

30

Fig. 1






Fig. 2



3/3

Fig. 3



V082.ST25.txt
SEQUENCE LISTING

<110> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW
<120> THE USE OF GENES ENCODING MEMBRANE TRANSPORTER PUMPS TO STIMULATE THE PRODUCTION
OF SECONDARY METABOLITES IN BIOLOGICAL CELLS
<130> DI/ABC/V082
<150> EP01201407.2
<151> 2001-04-18
<160> 15
<170> PatentIn version 3.1
<210> 1
<211> 4571
<212> DNA
<213> *Hyoscyamus muticus*
<220>
<221> CDS
<222> (133)..(4407)
<223>

<400> 1 atataactaa cttcacccat tattcattca ttatcaacaa aataatccat ttttatcaa aacttgaagg tgggttaca agacacaact aatattaatt gctgcattt aatttaatct tgggttcca ac atg gag cca tca gat tta agt aat ttc cga ggt cga agt Met Glu Pro Ser Asp Leu Ser Asn Phe Arg Gly Arg Ser 1 5 10	60
atg aga gga agt atg aga gga agt gta agg gaa aat agt aac tca ata Met Arg Gly Ser Met Arg Gly Ser Val Arg Glu Asn Ser Asn Ser Ile 15 20 25	120
tgg agg aac aat gga gtt gaa ata ttt tca aga tca act aga gat gaa Trp Arg Asn Asn Gly Val Glu Ile Phe Ser Arg Ser Thr Arg Asp Glu 30 35 40 45	171
gat gat gaa gag gca tta aaa tgg gca gca ctt gag aaa tta cca aca Asp Asp Glu Glu Ala Leu Lys Trp Ala Ala Leu Glu Lys Leu Pro Thr 50 55 60	219
tat gat aga tta aga aaa ggt ata ttg ttt gga tca caa ggt act ggt Tyr Asp Arg Leu Arg Lys Gly Ile Leu Phe Gly Ser Gln Gly Thr Gly 65 70 75	267
gtt gct gaa gtt gat gta gat gat ctt ggt gtt caa caa agg aag aat Val Ala Glu Val Asp Val Asp Leu Gly Val Gln Gln Arg Lys Asn 80 85 90	315
ttg ctt gac aga ctt gtt aaa att gct gaa gaa gat aat gag aag ttc Leu Leu Asp Arg Leu Val Lys Ile Ala Glu Glu Asp Asn Glu Lys Phe 95 100 105	363
ttg ttg aaa ctc aag aac agg att gac agg gtt ggg att gat ttt cca Leu Leu Lys Leu Lys Asn Arg Ile Asp Arg Val Gly Ile Asp Phe Pro 110 115 120 125	411
tct ata gaa gtg aga ttt gag cat ctg aat att gag gca gat gca tat Ser Ile Glu Val Arg Phe Glu His Leu Asn Ile Glu Ala Asp Ala Tyr 130 135 140	507
	555

V082.ST25.txt

gtt ggt agc aga gct ttg cct aca ttt acc aac ttc att tct aac ttc Val Gly Ser Arg Ala Leu Pro Thr Phe Thr Asn Phe Ile Ser Asn Phe	603
145 150 155	
att gag tcc ctg ctg gat tca ctt cac atc ctt cca tcg aaa aaa cgt Ile Glu Ser Leu Leu Asp Ser Leu His Ile Leu Pro Ser Lys Lys Arg	651
160 165 170	
tca gtt aca att ctc aag gat gtt agt ggt atc gtc aag ccc tgt cga Ser Val Thr Ile Leu Lys Asp Val Ser Gly Ile Val Lys Pro Cys Arg	699
175 180 185	
atg act ctg ctt tta gga cct cca ggt tct ggg aaa aca act ttg tta Met Thr Leu Leu Leu Gly Pro Pro Gly Ser Gly Lys Thr Thr Leu Leu	747
190 195 200 205	
ctt gct ttg gct gga aaa ctt gat tct gct cta agg gtt acg ggg aag Leu Ala Leu Ala Gly Lys Leu Asp Ser Ala Leu Arg Val Thr Gly Lys	795
210 215 220	
gtg acg tat aat gga cac gaa tta cat gaa ttt gtg cca caa aga act Val Thr Tyr Asn Gly His Glu Leu His Glu Phe Val Pro Gln Arg Thr	843
225 230 235	
gcg gcc tat att agc cag cat gat ttg cat att gga gaa atg act gtc Ala Ala Tyr Ile Ser Gln His Asp Leu His Ile Gly Glu Met Thr Val	891
240 245 250	
aga gaa act ttg gag ttc tct gca aga tgc caa gga gtt ggt tct cgt Arg Glu Thr Leu Glu Phe Ser Ala Arg Cys Gln Gly Val Gly Ser Arg	939
255 260 265	
tac gaa atg ttg gcc gaa ctg tca aga aga gag aaa gcg gct aat atc Tyr Glu Met Leu Ala Glu Leu Ser Arg Arg Glu Lys Ala Ala Asn Ile	987
270 275 280 285	
aaa cca gat gct gat att gac atg ttc atg aag gct gca tca act gaa Lys Pro Asp Ala Asp Ile Asp Met Phe Met Lys Ala Ala Ser Thr Glu	1035
290 295 300	
ggg caa gaa gcc aaa gtg att act gat tat gtt ctt aag att ctg gga Gly Gln Glu Ala Lys Val Ile Thr Asp Tyr Val Leu Lys Ile Leu Gly	1083
305 310 315	
ctg gat att tgt gca gat act atg gtg gga gat caa atg ata agg ggt Leu Asp Ile Cys Ala Asp Thr Met Val Gly Asp Gln Met Ile Arg Gly	1131
320 325 330	
att tca gga gga cag aag cgt gtc act act ggt gaa atg att gtc Ile Ser Gly Gly Gln Lys Lys Arg Val Thr Thr Gly Glu Met Ile Val	1179
335 340 345	
gga ccg tct aaa gcc ctt ttc atg gat gaa att tca act gga ctt gac Gly Pro Ser Lys Ala Leu Phe Met Asp Glu Ile Ser Thr Gly Leu Asp	1227
350 355 360 365	
agt tcc aca act tac tcc atc gtg aat tcc cta aag caa tct gtt caa Ser Ser Thr Thr Tyr Ser Ile Val Asn Ser Leu Lys Gln Ser Val Gln	1275
370 375 380	
atc ttg aaa gga aca gct ctg att tct ctc ttg cag cct gcc ccc gag Ile Leu Lys Gly Thr Ala Leu Ile Ser Leu Leu Gln Pro Ala Pro Glu	1323
385 390 395	
act tac aac ttg ttc gat gat att gtt ctg cta tca gat ggc tac att Thr Tyr Asn Leu Phe Asp Asp Ile Val Leu Leu Ser Asp Gly Tyr Ile	1371
400 405 410	

V082.ST25.txt

gtt tat cag ggt cca cga gag gaa gtg ctc gat ttc ttt gaa tcc atg Val Tyr Gln Gly Pro Arg Glu Glu Val Leu Asp Phe Phe Glu Ser Met 415 420 425	1419
gga ttc aaa tgc ccc aac aga aaa ggc gtg gct gac ttc ttg caa gaa Gly Phe Lys Cys Pro Asn Arg Lys Gly Val Ala Asp Phe Leu Gln Glu 430 435 440 445	1467
gtt aca tct aag aag gat caa cag caa tat tgg gta aag agg gac gag Val Thr Ser Lys Lys Asp Gln Gln Tyr Trp Val Lys Arg Asp Glu 450 455 460	1515
cct tat agg ttt att aca tca aaa gaa ttt gct gag gct tat caa tct Pro Tyr Arg Phe Ile Thr Ser Lys Glu Phe Ala Glu Ala Tyr Gln Ser 465 470 475	1563
ttc cat gtt ggg aga aaa gta agc gat gaa ctt aca acc gca ttt gac Phe His Val Gly Arg Lys Val Ser Asp Glu Leu Thr Thr Ala Phe Asp 480 485 490	1611
aag agc aaa agc cac cct gct gct ttg act act gaa aag tat ggt att Lys Ser Lys Ser His Pro Ala Ala Leu Thr Thr Glu Lys Tyr Gly Ile 495 500 505	1659
gga gtg aaa caa ctt ttg aag gtt tgc acg gaa aga gag ttc ctt cta Gly Val Lys Gln Leu Leu Lys Val Cys Thr Glu Arg Glu Phe Leu Leu 510 515 520 525	1707
atg cag agg aat tca ttt gtt tac atc ttc aaa ttc ttt cag ctt atg Met Gln Arg Asn Ser Phe Val Tyr Ile Phe Lys Phe Phe Gln Leu Met 530 535 540	1755
gta att gca ctt atg aca atg acc ata ttt ttt cga act aag atg tct Val Ile Ala Leu Met Thr Met Thr Ile Phe Phe Arg Thr Lys Met Ser 545 550 555	1803
cgg gat act gag acc gat gga gga att tat tct ggt gct ctc ttt ttt Arg Asp Thr Glu Thr Asp Gly Gly Ile Tyr Ser Gly Ala Leu Phe Phe 560 565 570	1851
acg gtt gtt atg ctt atg ttt aat ggt ttg tct gag ctt cct ttg aca Thr Val Val Met Leu Met Phe Asn Gly Leu Ser Glu Leu Pro Leu Thr 575 580 585	1899
ctc tac aag ctc ccg gtc ttc tac aag caa agg gac ttt ctc ttc tat Leu Tyr Lys Leu Pro Val Phe Tyr Lys Gln Arg Asp Phe Leu Phe Tyr 590 595 600 605	1947
cct tca tgg gct tat gca gtt cct tca tgg atc cta aaa atc cct gta Pro Ser Trp Ala Tyr Ala Val Pro Ser Trp Ile Leu Lys Ile Pro Val 610 615 620	1995
act ttt ctt gaa gtt ggg atg tgg gtg ttt ctc acc tat tat gtc atc Thr Phe Leu Glu Val Gly Met Trp Val Phe Leu Thr Tyr Tyr Val Ile 625 630 635	2043
gga ttt gat cct aat gtt gga aga ttt ttc aaa caa ttt ttg cta ctc Gly Phe Asp Pro Asn Val Gly Arg Phe Phe Lys Gln Phe Leu Leu Leu 640 645 650	2091
ata gta gta aac cag atg gca tca gga ttg ttc agg ttt att gca gca Ile Val Val Asn Gln Met Ala Ser Gly Leu Phe Arg Phe Ile Ala Ala 655 660 665	2139
gtt gga agg acc atg gga gtt gct agc aca ttt gga gca ttt gcg ctg Val Gly Arg Thr Met Gly Val Ala Ser Thr Phe Gly Ala Phe Ala Leu 670 675 680 685	2187

V082.ST25.txt

ctt tta caa ttt gca ttg ggc ggt ttt gtc ctt gca cga act gac gtg Leu Leu Gln Phe Ala Leu Gly Gly Phe Val Leu Ala Arg Thr Asp Val 690 695 700	2235
aag gac tgg tgg att tgg gga tac tgg acc tca cca ctt atg ttc tca Lys Asp Trp Trp Ile Trp Gly Tyr Trp Thr Ser Pro Leu Met Phe Ser 705 710 715	2283
gtg aat gca atc ctt gtg aat gaa ttt gac gga aaa aag tgg aaa cat Val Asn Ala Ile Leu Val Asn Glu Phe Asp Gly Lys Lys Trp Lys His 720 725 730	2331
att gcg cca aat gga act gag ccg ctt gga cct gca gtg gta aga tct Ile Ala Pro Asn Gly Thr Glu Pro Leu Gly Pro Ala Val Val Arg Ser 735 740 745	2379
caa ggg ttc ttt ccc gat gca tat tgg tac tgg ata ggt gta ggt gca Gln Gly Phe Phe Pro Asp Ala Tyr Trp Tyr Trp Ile Gly Val Gly Ala 750 755 760 765	2427
ctt gtt gga ttc aca gtt ctg ttt aac ata gcc tac agt ctt gct ctc Leu Val Gly Phe Thr Val Leu Phe Asn Ile Ala Tyr Ser Leu Ala Leu 770 775 780	2475
gct tat ctt aac cca ttc gga aag cca caa gct aca att tca gaa gaa Ala Tyr Leu Asn Pro Phe Gly Lys Pro Gln Ala Thr Ile Ser Glu Glu 785 790 795	2523
agt gag agc aac gaa aat agt gaa tta tca acc cca ata gct agt aca Ser Glu Ser Asn Glu Asn Ser Glu Leu Ser Thr Pro Ile Ala Ser Thr 800 805 810	2571
acg gaa gga gat tct gtc ggt gag aat cag aat aag aaa gga atg gtt Thr Glu Gly Asp Ser Val Gly Glu Asn Gln Asn Lys Lys Gly Met Val 815 820 825	2619
ctt cca ttt gaa ccc cat tcc atc acc ttt gat gaa gtt gta tac tca Leu Pro Phe Glu Pro His Ser Ile Thr Phe Asp Glu Val Val Tyr Ser 830 835 840 845	2667
gtt gac atg cct ccg gaa atg aga gag caa ggt acc agt gac aat aga Val Asp Met Pro Pro Glu Met Arg Glu Gln Gly Thr Ser Asp Asn Arg 850 855 860	2715
ttg gta ctt ttg aag agt gtg agt gga gct ttc agg cca ggt gtt ctc Leu Val Leu Leu Lys Ser Val Ser Gly Ala Phe Arg Pro Gly Val Leu 865 870 875	2763
aca gct ctg atg gga gtt agt gga gcc ggt aaa aca aca ttg atg gat Thr Ala Leu Met Gly Val Ser Gly Ala Gly Lys Thr Thr Leu Met Asp 880 885 890	2811
gtc tta gct gga agg aaa act gga ggt tac att gac gga agc att aac Val Leu Ala Gly Arg Lys Thr Gly Gly Tyr Ile Asp Gly Ser Ile Asn 895 900 905	2859
att tct gga tat ccc aag aag caa gaa aca ttt gca cgt att tct gga Ile Ser Gly Tyr Pro Lys Lys Gln Glu Thr Phe Ala Arg Ile Ser Gly 910 915 920 925	2907
tac tgt gaa caa aac gac atc cat tca cct tat gta aca gtt tat gag Tyr Cys Glu Gln Asn Asp Ile His Ser Pro Tyr Val Thr Val Tyr Glu 930 935 940	2955
tcc ttg gtt tac tcg gct tgg ctg cgt tta cct caa gac gtt gat gag Ser Leu Val Tyr Ser Ala Trp Leu Arg Leu Pro Gln Asp Val Asp Glu 945 950 955	3003

V082.ST25.txt

aaa aag cga atg atg ttc gtt gaa caa gtt atg gaa ctt gtg gag ctt Lys Lys Arg Met Met Phe Val Glu Gln Val Met Glu Leu Val Glu Leu 960 965 970	3051
aca cca cta aga tct gcc tta gtc ggg ttg cca gga gtt aat ggt ctg Thr Pro Leu Arg Ser Ala Leu Val Gly Leu Pro Gly Val Asn Gly Leu 975 980 985	3099
acg att gca gtt gaa cta gta gca aac ccc tct atc att ttt atg gac Thr Ile Ala Val Glu Leu Val Ala Asn Pro Ser Ile Ile Phe Met Asp 990 995 1000 1005	3147
gaa cca act tca gga ttg gat gca aga gct gct gca att gtg atg Glu Pro Thr Ser Gly Leu Asp Ala Arg Ala Ala Ala Ile Val Met 1010 1015 1020	3192
aga gct gtt agg aac act gtc gat aca ggg aga act gtt gtt tgt Arg Ala Val Arg Asn Thr Val Asp Thr Gly Arg Thr Val Val Cys 1025 1030 1035	3237
acc att cat cag cct agc att gac att ttt gag gcg ttc gat gag Thr Ile His Gln Pro Ser Ile Asp Ile Phe Glu Ala Phe Asp Glu 1040 1045 1050	3282
tta ttt ctt atg aaa cga gga gga caa gag ata tac gtc ggt cca Leu Phe Leu Met Lys Arg Gly Gly Gln Glu Ile Tyr Val Gly Pro 1055 1060 1065	3327
tta ggt cgt gag tca agc cat ttg ata aag tat ttt gag tct ata Leu Gly Arg Glu Ser Ser His Leu Ile Lys Tyr Phe Glu Ser Ile 1070 1075 1080	3372
ccc ggt gta acc aaa ata aag gag ggg tac aat cca gca act tgg Pro Gly Val Thr Lys Ile Lys Glu Gly Tyr Asn Pro Ala Thr Trp 1085 1090 1095	3417
atg tta gaa gtc aca tct tcg tct caa gaa ata aca tta ggt gtt Met Leu Glu Val Thr Ser Ser Ser Gln Glu Ile Thr Leu Gly Val 1100 1105 1110	3462
gat ttt acc gaa tta tac aag aac tca gac ctc ttc cgg agg aac Asp Phe Thr Glu Leu Tyr Lys Asn Ser Asp Leu Phe Arg Arg Asn 1115 1120 1125	3507
aaa gct ttg atc gag gaa cta agt gtg cca cgc cct ggt aca agt Lys Ala Leu Ile Glu Glu Leu Ser Val Pro Arg Pro Gly Thr Ser 1130 1135 1140	3552
gac ctg cat ttt gaa act gaa ttc tca cag cca ttt tgg gtc caa Asp Leu His Phe Glu Thr Glu Phe Ser Gln Pro Phe Trp Val Gln 1145 1150 1155	3597
tgt atg gct tgt ttg tgg aag caa cac tgg tca tac tgg cgt aat Cys Met Ala Cys Leu Trp Lys Gln His Trp Ser Tyr Trp Arg Asn 1160 1165 1170	3642
ccg gct tat act gca gtc aga ttt ctc ttc aca acc ttc ata gct Pro Ala Tyr Thr Ala Val Arg Phe Leu Phe Thr Thr Phe Ile Ala 1175 1180 1185	3687
ctc ata ttc ggg tca atg ttc tgg gat att ggt aca aaa gtg agt Leu Ile Phe Gly Ser Met Phe Trp Asp Ile Gly Thr Lys Val Ser 1190 1195 1200	3732
ggg ccc caa gat ctg aaa aac gcc atg gga tct atg tat gct gct Gly Pro Gln Asp Leu Lys Asn Ala Met Gly Ser Met Tyr Ala Ala 1205 1210 1215	3777

V082.ST25.txt

gtc ctc ttc ctt ggt	gtg cag aat tca tcg	tca gtt cag ccc gtt	3822
Val Leu Phe Leu Gly	Val Gln Asn Ser Ser	Ser Val Gln Pro Val	
1220	1225	1230	
gta tct gtc gaa cgt	act gta ttt tac aga	gaa aaa gct gct gga	3867
Val Ser Val Glu Arg	Thr Val Phe Tyr Arg	Glu Lys Ala Ala Gly	
1235	1240	1245	
atg tac tcc gcg atg	ccc tat gcc ttt gca	caa gtt ttc atc gaa	3912
Met Tyr Ser Ala Met	Pro Tyr Ala Phe Ala	Gln Val Phe Ile Glu	
1250	1255	1260	
att cct tat gta ttt	gta caa gct gtt gtc	tat ggt ctc att gtc	3957
Ile Pro Tyr Val Phe	Val Gln Ala Val Val	Tyr Gly Leu Ile Val	
1265	1270	1275	
tat tct atg att gga	ttt gaa tgg act gct	gca aaa ttc ttt tgg	4002
Tyr Ser Met Ile Gly	Phe Glu Trp Thr Ala	Ala Lys Phe Phe Trp	
1280	1285	1290	
tac ttc ttc ttc atg	ttc ttc acc ttc ctc	tac ttc acc ttc ttt	4047
Tyr Phe Phe Phe Met	Phe Phe Thr Phe Leu	Tyr Phe Thr Phe Phe	
1295	1300	1305	
ggc atg atg acc gtg	gct gtt acc ccg aac	caa aat gtt gct tca	4092
Gly Met Met Thr Val	Ala Val Thr Pro Asn	Gln Asn Val Ala Ser	
1310	1315	1320	
atc gtt gcc gga ttc	ttc tat aca gta tgg	aat ctc ttc tca gga	4137
Ile Val Ala Gly Phe	Phe Tyr Thr Val Trp	Asn Leu Phe Ser Gly	
1325	1330	1335	
ttc atc gtt cca cga	cct cgt att ccg ata	tgg tgg aga tgg tac	4182
Phe Ile Val Pro Arg	Pro Arg Ile Pro Ile	Trp Trp Arg Trp Tyr	
1340	1345	1350	
tac tgg gct tgc cct	gtt gca tgg aca ttg	tat ggt ttg gtt gca	4227
Tyr Trp Ala Cys Pro	Val Ala Trp Thr Leu	Tyr Gly Leu Val Ala	
1355	1360	1365	
tct caa ttt gga gac	ctc caa gat aca att	aat gat caa act gtg	4272
Ser Gln Phe Gly Asp	Leu Gln Asp Thr Ile	Asn Asp Gln Thr Val	
1370	1375	1380	
gaa gat ttc ttg aga	agt agc tat gga ttt	aag cat gat ttt cta	4317
Glu Asp Phe Leu Arg	Ser Ser Tyr Gly Phe	Lys His Asp Phe Leu	
1385	1390	1395	
gga gtt gtt gca gct	gtg atc gtt gca ttt	gca gtt gtt ttc gcc	4362
Gly Val Val Ala Ala	Val Ile Val Ala Phe	Ala Val Val Phe Ala	
1400	1405	1410	
ttc aca ttt gct ttg	ggt atc aag gca ttc	aat ttc cag aga aga	4407
Phe Thr Phe Ala Leu	Gly Ile Lys Ala Phe	Asn Phe Gln Arg Arg	
1415	1420	1425	
tagaaaatagt atttatttgt	attccccagtt gttcatatat	tcttgaataa gcttatgaag	4467
ttttaagttt ctgaatatgt	tatgtcttac taatcttct	caattccccag ttttggta	4527
taataaacatg taataattgt	tattcaaaaa aaaaaaaaaa	aaaa	4571

<210> 2
 <211> 1425
 <212> PRT
 <213> Hyoscyamus muticus

V082.ST25.txt

<400> 2

Met Glu Pro Ser Asp Leu Ser Asn Phe Arg Gly Arg Ser Met Arg Gly
1 5 10 15

Ser Met Arg Gly Ser Val Arg Glu Asn Ser Asn Ser Ile Trp Arg Asn
20 25 30

Asn Gly Val Glu Ile Phe Ser Arg Ser Thr Arg Asp Glu Asp Asp Glu
35 40 45

Glu Ala Leu Lys Trp Ala Ala Leu Glu Lys Leu Pro Thr Tyr Asp Arg
50 55 60

Leu Arg Lys Gly Ile Leu Phe Gly Ser Gln Gly Thr Gly Val Ala Glu
65 70 75 80

Val Asp Val Asp Asp Leu Gly Val Gln Gln Arg Lys Asn Leu Leu Asp
85 90 95

Arg Leu Val Lys Ile Ala Glu Glu Asp Asn Glu Lys Phe Leu Leu Lys
100 105 110

Leu Lys Asn Arg Ile Asp Arg Val Gly Ile Asp Phe Pro Ser Ile Glu
115 120 125

Val Arg Phe Glu His Leu Asn Ile Glu Ala Asp Ala Tyr Val Gly Ser
130 135 140

Arg Ala Leu Pro Thr Phe Thr Asn Phe Ile Ser Asn Phe Ile Glu Ser
145 150 155 160

Leu Leu Asp Ser Leu His Ile Leu Pro Ser Lys Lys Arg Ser Val Thr
165 170 175

Ile Leu Lys Asp Val Ser Gly Ile Val Lys Pro Cys Arg Met Thr Leu
180 185 190

Leu Leu Gly Pro Pro Gly Ser Gly Lys Thr Thr Leu Leu Ala Leu
195 200 205

Ala Gly Lys Leu Asp Ser Ala Leu Arg Val Thr Gly Lys Val Thr Tyr
210 215 220

Asn Gly His Glu Leu His Glu Phe Val Pro Gln Arg Thr Ala Ala Tyr
225 230 235 240

Ile Ser Gln His Asp Leu His Ile Gly Glu Met Thr Val Arg Glu Thr
245 250 255

Leu Glu Phe Ser Ala Arg Cys Gln Gly Val Gly Ser Arg Tyr Glu Met

V082.ST25.txt
260 265 270

Leu Ala Glu Leu Ser Arg Arg Glu Lys Ala Ala Asn Ile Lys Pro Asp
275 280 285

Ala Asp Ile Asp Met Phe Met Lys Ala Ala Ser Thr Glu Gly Gln Glu
290 295 300

Ala Lys Val Ile Thr Asp Tyr Val Leu Lys Ile Leu Gly Leu Asp Ile
305 310 315 320

Cys Ala Asp Thr Met Val Gly Asp Gln Met Ile Arg Gly Ile Ser Gly
325 330 335

Gly Gln Lys Lys Arg Val Thr Thr Gly Glu Met Ile Val Gly Pro Ser
340 345 350

Lys Ala Leu Phe Met Asp Glu Ile Ser Thr Gly Leu Asp Ser Ser Thr
355 360 365

Thr Tyr Ser Ile Val Asn Ser Leu Lys Gln Ser Val Gln Ile Leu Lys
370 375 380

Gly Thr Ala Leu Ile Ser Leu Leu Gln Pro Ala Pro Glu Thr Tyr Asn
385 390 395 400

Leu Phe Asp Asp Ile Val Leu Leu Ser Asp Gly Tyr Ile Val Tyr Gln
405 410 415

Gly Pro Arg Glu Glu Val Leu Asp Phe Phe Glu Ser Met Gly Phe Lys
420 425 430

Cys Pro Asn Arg Lys Gly Val Ala Asp Phe Leu Gln Glu Val Thr Ser
435 440 445

Lys Lys Asp Gln Gln Gln Tyr Trp Val Lys Arg Asp Glu Pro Tyr Arg
450 455 460

Phe Ile Thr Ser Lys Glu Phe Ala Glu Ala Tyr Gln Ser Phe His Val
465 470 475 480

Gly Arg Lys Val Ser Asp Glu Leu Thr Thr Ala Phe Asp Lys Ser Lys
485 490 495

Ser His Pro Ala Ala Leu Thr Thr Glu Lys Tyr Gly Ile Gly Val Lys
500 505 510

Gln Leu Leu Lys Val Cys Thr Glu Arg Glu Phe Leu Leu Met Gln Arg
515 520 525

Asn Ser Phe Val Tyr Ile Phe Lys Phe Phe Gln Leu Met Val Ile Ala
Page 8

V082.ST25.txt

530 535 540
Leu Met Thr Met Thr Ile Phe Phe Arg Thr Lys Met Ser Arg Asp Thr
545 550 555 560

Glu Thr Asp Gly Gly Ile Tyr Ser Gly Ala Leu Phe Phe Thr Val Val
565 570 575

Met Leu Met Phe Asn Gly Leu Ser Glu Leu Pro Leu Thr Leu Tyr Lys
580 585 590

Leu Pro Val Phe Tyr Lys Gln Arg Asp Phe Leu Phe Tyr Pro Ser Trp
595 600 605

Ala Tyr Ala Val Pro Ser Trp Ile Leu Lys Ile Pro Val Thr Phe Leu
610 615 620

Glu Val Gly Met Trp Val Phe Leu Thr Tyr Tyr Val Ile Gly Phe Asp
625 630 635 640

Pro Asn Val Gly Arg Phe Phe Lys Gln Phe Leu Leu Ile Val Val
645 650 655

Asn Gln Met Ala Ser Gly Leu Phe Arg Phe Ile Ala Ala Val Gly Arg
660 665 670

Thr Met Gly Val Ala Ser Thr Phe Gly Ala Phe Ala Leu Leu Leu Gln
675 680 685

Phe Ala Leu Gly Gly Phe Val Leu Ala Arg Thr Asp Val Lys Asp Trp
690 695 700

Trp Ile Trp Gly Tyr Trp Thr Ser Pro Leu Met Phe Ser Val Asn Ala
705 710 715 720

Ile Leu Val Asn Glu Phe Asp Gly Lys Lys Trp Lys His Ile Ala Pro
725 730 735

Asn Gly Thr Glu Pro Leu Gly Pro Ala Val Val Arg Ser Gln Gly Phe
740 745 750

Phe Pro Asp Ala Tyr Trp Tyr Trp Ile Gly Val Gly Ala Leu Val Gly
755 760 765

Phe Thr Val Leu Phe Asn Ile Ala Tyr Ser Leu Ala Leu Ala Tyr Leu
770 775 780

Asn Pro Phe Gly Lys Pro Gln Ala Thr Ile Ser Glu Glu Ser Glu Ser
785 790 795 800

Asn Glu Asn Ser Glu Leu Ser Thr Pro Ile Ala Ser Thr Thr Glu Gly

V082.ST25.txt

805

810

815

Asp Ser Val Gly Glu Asn Gln Asn Lys Lys Gly Met Val Leu Pro Phe
820 825 830

Glu Pro His Ser Ile Thr Phe Asp Glu Val Val Tyr Ser Val Asp Met
835 840 845

Pro Pro Glu Met Arg Glu Gln Gly Thr Ser Asp Asn Arg Leu Val Leu
850 855 860

Leu Lys Ser Val Ser Gly Ala Phe Arg Pro Gly Val Leu Thr Ala Leu
865 870 875 880

Met Gly Val Ser Gly Ala Gly Lys Thr Thr Leu Met Asp Val Leu Ala
885 890 895

Gly Arg Lys Thr Gly Gly Tyr Ile Asp Gly Ser Ile Asn Ile Ser Gly
900 905 910

Tyr Pro Lys Lys Gln Glu Thr Phe Ala Arg Ile Ser Gly Tyr Cys Glu
915 920 925

Gln Asn Asp Ile His Ser Pro Tyr Val Thr Val Tyr Glu Ser Leu Val
930 935 940

Tyr Ser Ala Trp Leu Arg Leu Pro Gln Asp Val Asp Glu Lys Lys Arg
945 950 955 960

Met Met Phe Val Glu Gln Val Met Glu Leu Val Glu Leu Thr Pro Leu
965 970 975

Arg Ser Ala Leu Val Gly Leu Pro Gly Val Asn Gly Leu Thr Ile Ala
980 985 990

Val Glu Leu Val Ala Asn Pro Ser Ile Ile Phe Met Asp Glu Pro Thr
995 1000 1005

Ser Gly Leu Asp Ala Arg Ala Ala Ala Ile Val Met Arg Ala Val
1010 1015 1020

Arg Asn Thr Val Asp Thr Gly Arg Thr Val Val Cys Thr Ile His
1025 1030 1035

Gln Pro Ser Ile Asp Ile Phe Glu Ala Phe Asp Glu Leu Phe Leu
1040 1045 1050

Met Lys Arg Gly Gly Gln Glu Ile Tyr Val Gly Pro Leu Gly Arg
1055 1060 1065

Glu Ser Ser His Leu Ile Lys Tyr Phe Glu Ser Ile Pro Gly Val
Page 10

V082.ST25.txt

1070	1075	1080
Thr Lys Ile Lys Glu Gly Tyr Asn Pro Ala Thr Trp Met Leu Glu		
1085	1090	1095
Val Thr Ser Ser Ser Gln Glu Ile Thr Leu Gly Val Asp Phe Thr		
1100	1105	1110
Glu Leu Tyr Lys Asn Ser Asp Leu Phe Arg Arg Asn Lys Ala Leu		
1115	1120	1125
Ile Glu Glu Leu Ser Val Pro Arg Pro Gly Thr Ser Asp Leu His		
1130	1135	1140
Phe Glu Thr Glu Phe Ser Gln Pro Phe Trp Val Gln Cys Met Ala		
1145	1150	1155
Cys Leu Trp Lys Gln His Trp Ser Tyr Trp Arg Asn Pro Ala Tyr		
1160	1165	1170
Thr Ala Val Arg Phe Leu Phe Thr Thr Phe Ile Ala Leu Ile Phe		
1175	1180	1185
Gly Ser Met Phe Trp Asp Ile Gly Thr Lys Val Ser Gly Pro Gln		
1190	1195	1200
Asp Leu Lys Asn Ala Met Gly Ser Met Tyr Ala Ala Val Leu Phe		
1205	1210	1215
Leu Gly Val Gln Asn Ser Ser Ser Val Gln Pro Val Val Ser Val		
1220	1225	1230
Glu Arg Thr Val Phe Tyr Arg Glu Lys Ala Ala Gly Met Tyr Ser		
1235	1240	1245
Ala Met Pro Tyr Ala Phe Ala Gln Val Phe Ile Glu Ile Pro Tyr		
1250	1255	1260
Val Phe Val Gln Ala Val Val Tyr Gly Leu Ile Val Tyr Ser Met		
1265	1270	1275
Ile Gly Phe Glu Trp Thr Ala Ala Lys Phe Phe Trp Tyr Phe Phe		
1280	1285	1290
Phe Met Phe Phe Thr Phe Leu Tyr Phe Thr Phe Phe Gly Met Met		
1295	1300	1305
Thr Val Ala Val Thr Pro Asn Gln Asn Val Ala Ser Ile Val Ala		
1310	1315	1320
Gly Phe Phe Tyr Thr Val Trp Asn Leu Phe Ser Gly Phe Ile Val		

V082.ST25.txt

1325	1330	1335
 Pro Arg Pro Arg Ile Pro Ile Trp Trp Arg Trp Tyr Tyr Trp Ala 1340 1345 1350		
 Cys Pro Val Ala Trp Thr Leu Tyr Gly Leu Val Ala Ser Gln Phe 1355 1360 1365		
 Gly Asp Leu Gln Asp Thr Ile Asn Asp Gln Thr Val Glu Asp Phe 1370 1375 1380		
 Leu Arg Ser Ser Tyr Gly Phe Lys His Asp Phe Leu Gly Val Val 1385 1390 1395		
 Ala Ala Val Ile Val Ala Phe Ala Val Val Phe Ala Phe Thr Phe 1400 1405 1410		
 Ala Leu Gly Ile Lys Ala Phe Asn Phe Gln Arg Arg 1415 1420 1425		
 <210> 3		
<211> 40		
<212> DNA		
<213> Artificial Sequence		
 <220>		
<223> forward primer in example 3.1		
 <400> 3		
aaaaagcagg ctaccatgcc cgaggccaag cttaacaata		40
 <210> 4		
<211> 40		
<212> DNA		
<213> Artificial Sequence		
 <220>		
<223> reverse primer of example 3.1		
 <400> 4		
agaaagctgg gtccatcttg gtaagttct tttcttaacc		40
 <210> 5		
<211> 37		
<212> PRT		
<213> Ipomoea batatas		
 <300>		
<301> Matsuoka and Nakamura		
<302> Propeptide of a precursor to a plant vacuolar protein required for vacuol		
ar		
targeting		
<303> Proc. Natl. Acad. Sci. USA		
<304> 88		
<305> 3		
<306> 834-8		
<307> 1991-02-01		
<308> PMID: 1992474		
<309> 1991-02-01		

V082.ST25.txt

<313> (1)..(37)

<400> 5

Met Lys Ala Phe Thr Leu Ala Leu Phe Leu Ala Leu Ser Leu Tyr Leu
1 5 10 15

Leu Pro Asn Pro Ala His Ser Arg Phe Asn Pro Ile Arg Leu Pro Thr
20 25 30

Thr His Glu Pro Ala
35

<210> 6

<211> 12

<212> PRT

<213> Nicotiana tabacum

<300>

<301> Neuhaus, J.M.; Sticher, L.; Meins, F. and Boller, T.
<302> A short C-terminal sequence is necessary and sufficient for the targeting
of

chitinases to the plant vacuole

<303> Proc. Natl. Acad. Sci. USA

<304> 88

<305> 22

<306> 10362-10366

<307> 1991-11-15

<308> PMID: 1946457

<309> 1991-11-25

<313> (318)..(329)

<400> 6

Asp Leu Leu Gly Asn Gly Leu Leu Val Asp Thr Met
1 5 10

<210> 7

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> forward primer in example 5.1

<400> 7

aaaaagcagg ctaccatgga gacgttatcg agaa

34

<210> 8

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> reverse primer in example 5.1

<400> 8

agaaaagctgg gtctatatgtt gttggaaatgg gacg

34

<210> 9

<211> 12789

<212> DNA

V082.ST25.txt

<213> Artificial Sequence

<220>

<223> vector pK7WG2D

<220>

<221> misc_feature

<222> (4772)..(4772)

<223> n can be any base

<400> 9		
tgatcacagg cagcaacgct ctgtcatcgtaacaatcaac atgctaccct ccgcgagatc	60	
atccgtgttt caaacccggc agcttagttg ccgttcttcc gaatagcatc ggtAACATGA	120	
gcaaagtctg ccgccttaca acggctctcc cgctgacgcc gtcccggact gatgggctgc	180	
ctgtatcgag tggtgatttt gtgccgagct gccggcggg gagctgttgg ctggctggtg	240	
gcaggatata ttgtggtgta aacaaattga cgcttagaca acttaataac acattgcgga	300	
cgTTTAAAT gtactgaatt aacGCCGAAT tgaattatca gcttgcATGC CGGTGATCT	360	
agtaacatAG atgacACCgc GCGCgATAAT ttatCCTAGT ttgcgcgcta tATTTGTTT	420	
tctatcgct attaaatgtta taattgcggg actctaatac AAAAACCCAT CTCATAAATA	480	
acgtcatgca ttacatgtta attattacat gcttaACGTA ATTCAACAGA AATTATATGA	540	
taatcatcgc aagaccggca acaggattca atcttaagaa actttattgc caaatgttg	600	
aacgatctgc ttgactctag cttagtCCG aACCCAGAG TCCCgCTAG aagaACTCGT	660	
caagaaggcg atagaaggcg atgcgctgcg aatcgggagc ggcgataccg taaAGCACGA	720	
ggaAGCGGTC AGCCCATTCG CCGCCAAGCT CTTCAGCAAT ATCACGGTA GCCAACGCTA	780	
TGTCCGTATA GCGGTCCGCC ACACCCAGCC GGCCACAGTC GATGAATCCA GAAAAGCGGC	840	
CATTTCCAC CATGATATTG GGCAAGCAGG CATGCCCTG GGTACGACG AGATCCTCGC	900	
CGTCGGGCACT CGCGCCCTTG AGCCTGGCGA ACAGTTGGC TGGCGCGAGC CCCTGATGCT	960	
CTTCGTCCAG ATCATCCTGA TCGACAAGAC CGGCTTCCAT CGAGTACGT CCTCGCTCGA	1020	
TGCGATGTTT CGCTTGGTGG TCGAAATGGC AGGTAGCCGG ATCAAGCGTA TGCAAGCCGC	1080	
GCATTGCTAC AGCCATGATG GATACTTTCT CGGCAGGAGC AAGGTGAGAT GACAGGAGAT	1140	
CCTGCCCCGG CACTTCGCCA AATAGCAGCC AGTCCTTCC CGCTTCAGTG ACAACGTCGA	1200	
GCACAGCTGC GCAAGGAAACG CCCGTCGTGG CCAGGCCACGA TAGCCGCGCT GCCTCGTCTT	1260	
GGAGTTCACTT CAGGGCACCG GACAGGTCGG TCTTGACAAA AAGAACCGGG CGCCCGTGC	1320	
CTGACAGCCG GAACACGGCG GCATCAGAGC AGCCGATTGT CTGTTGTGCC CAGTCATAGC	1380	
CGAATAGCCT CTCCACCCAA GCGGCCGGAG AACCTGCGTG CAATCCATCT TGTTCATCA	1440	
TGCTCGATC GAGTTGAGAG TGAATATGAG ACTCTAATTG GATAACCGAGG GGAATTATG	1500	
GAACGTCAGT GGAGCATTAA TGACAAGAAA TATTGCTAG CTGATAGTGA CCTTAGGCAG	1560	
CTTTGAACG CGCAATAATG GTTCTGACG TATGTGCTTA GCTCATTAAA CTCCAGAAAC	1620	
CCGCGGCTGA GTGGCTCCTT CAACGTTGCG GTTCTGTCAG TTCCAAACGT AAAACGGCTT	1680	

V082.ST25.txt

gtccccgcgtc atccggcgaaaa gtcataacgt gactccctta attctcatgt atgataattc	1740
gccccgtacccg gggatccctct agagggcccg acgtcgcatg cctgcaggc actggatttt	1800
ggtttttagga attagaaatt ttattgatag aagtattttt caaatacaaaa tacataactaa	1860
gggttctta tatgctcaac acatgagcga aaccctataa gaaccctaat tcccttatct	1920
gggaactact cacacattat tctggagaaa aatagagaga gatagattt tagagagaga	1980
ctggtgattt ttgcggactc tagcatggcc gcgggatatc accactttgt acaagaaagc	2040
tgaacgagaa acgtaaaatg atataaatat caatatatta aatttagattt tgcataaaaaa	2100
acagactaca taatactgtt aaacacaaca tatccagtca ctatggtcga cctgcagact	2160
ggctgtgtat aagggagcct gacattata ttccccagaa catcaggtt atggcgaaaa	2220
tgtatgtcatt ttgcgggtgg ctgagatcag ccacttcttc cccgataacg gagaccggca	2280
cactggccat atccgggttc atcatgcgcc agctttcatc cccgatatgc accaccgggt	2340
aaagttcacg ggagacttta tctgacagca gacgtgcact gcccaggggg atcaccatcc	2400
gtcgccccggg cgtgtcaata atatcactct gtacatccac aaacagacga taacggctct	2460
ctctttata ggtgtaaacc tttaactgca ttccaccagt ccctgttctc gtcagaaaa	2520
gagccgttca ttcaataaaa ccggggcgacc tcagccatcc cttcctgatt ttccgctttc	2580
cagcgttcgg cacgcagacg acgggcttca ttctgcatgg ttgtgcttac cagaccggag	2640
atattgacat catatatgcc ttgagcaact gatagtgtc gtcactgtaa	2700
tacgctgctt catagcacac ctcttttga catacttcgg gtatacatat cagtataat	2760
tcttataccg caaaaatcag cgcgcaaata cgcatactgt tatctggctt ttagtaagcc	2820
ggatccacgc gtttacgccc cgccctgcca ctcatcgcat tactgttgcattt attcattha	2880
cattctgccc acatggaagc catcacagac ggcatgatga acctgaatcg ccagcggcat	2940
cagcaccttg tcgccttgcg tataatattt gccatggtg aaaacggggg cgaagaagtt	3000
gtccatattt gccacgttta aatcaaaaact ggtgaaactc acccaggat tggctgagac	3060
aaaaaacata ttctcaataa accctttagg gaaataggcc aggttttcac cgtaacacgc	3120
cacatcttgc gaatataatgt gtagaaaactg ccggaaatcg tcgtggattt cactccagag	3180
cgtgaaaac gtttcagttt gctcatggaa aacgggttaa caagggtgaa cactatccca	3240
tatcaccagc tcaccgtctt tcattgcatt acggattcc ggatgagcat tcattcaggcg	3300
ggcaagaatg tgaataaaagg ccggataaaa cttgtgcttta tttttcttta cggctttaa	3360
aaaggccgta atatccagct gaacggctcg gttataggtt cattgagcaa ctgactgaaa	3420
tgcctcaaaa tggctttac gatgccattt ggtatataca acgggtgtat atccagtgtat	3480
ttttttctcc atttttagctt ccttagctcc tgaaaatctc gccggatcct aactcaaaat	3540
ccacacattt tacgagccgg aagcataaaag tgtaaagcct ggggtgccta atgcggccgc	3600
catagtgact ggatatgtt gtttttacag tattatgtt tctgtttttt atgcaaaatc	3660
taatttaata tattgatattt tataatcattt tacgtttctc gttcagctt tttgtacaaa	3720

V082.ST25.txt

cttgtgatat cactagtgcg	gccgcctgca	ggtcgactag	aatagtaaat	tgttatgtt	3780
tttgttgtt	gttttgtgt	ggtaattgtt	gtaaaaatac	ggatcgccct	3840
ccaaatgaaa	tgaacttcct	tatatagagg	aagggtctt	cgaaggatag	3900
cgtcatccct	tacgtcagt	gagatatcac	atcaatccac	ttgcttgaa	3960
gaacgtctc	ttttccacg	atgctcctcg	tgggtgggg	tccatcttg	4020
cggcagaggc	atcttgaacg	atagccttc	ctttatcgca	atgatggcat	4080
cacccctt	ttctactgtc	cttttgatga	agtgacagat	agctggcaa	4140
ggaggttcc	cgatattacc	ctttgttcaa	aagtctcaat	agcccttgg	4200
ctgtatctt	gatattctt	gagtagacga	gagtgtcgt	ctccaccatg	4260
ttttcttctt	gtcattgagt	cgtaaaagac	tctgtatgaa	ctgttcgcca	4320
cgagttctgt	tagatcctcg	atctgaattt	ttgactccat	ggccttggat	4380
ctactttctt	agagactcca	atctctatta	cttgccttgg	tttatgaagc	4440
tcgtccatac	tggaatagta	cttctgatct	tgagaaatat	atctttctct	4500
tgcagttagt	cctgaatctt	ttgactgcat	ctttaacctt	cttgggaagg	4560
cctggagatt	attactcggg	tagatcgct	tgatgagacc	tgccgcgtag	4620
ccatctgtgg	gtcagcattc	tttctgaaat	tgaagaggct	aatcttctca	4680
tgaacatgg	atcgtcacct	tctccgtcga	actttctcc	tagatcgtag	4740
agtcgtccat	ggtgatctcc	ggggcaaagg	anatctcgac	catatggag	4800
tgcattgcctg	caggtcactg	gattttggtt	ttaggaatta	gaaattttat	4860
attttacaaa	tacaaataca	tactaagggt	ttcttatatg	ctcaacacat	4920
ctataagaac	cctaattccc	ttatgtggga	actactcaca	cattattctg	4980
gagagagata	gattttaga	gagagactgg	tgattttgc	ggactctaga	5040
ccccgggct	gcagccgggc	ggcgcttaca	gctcgccctt	cttgcacage	5100
cgagagtgtat	cccgccggcg	gtcacgaact	ccagcaggac	catgtgatcg	5160
tggggtcttt	gctcagggcg	gactgggtgc	tcaggttagt	gttgcgggc	5220
ggccgtcgcc	gatgggggtg	ttctgctggt	agtggtcggc	gagctgcacg	5280
cgatgtgtg	gccccatctt	aagttcacct	tgtatccgtt	cttctgttt	5340
tatagacgtt	gtggctgtt	tagttgtact	ccagcttgt	ccccaggatg	5400
ccttgaagtc	gatgccttc	agctcgatgc	ggttcaccag	gggtgcggcc	5460
cctcggccgc	ggtcttgcgt	ttgcgcgt	ccttgaagaa	gatggtcgc	5520
agccttcggg	catggccgac	ttgaagaagt	cgtgtgcgtt	catgtggtcg	5580
tgaagcactg	cacgcctgt	gtcagggtgg	tcacgagggt	gggccagggc	5640
tgccgggttgt	gcagatgaac	ttcagggtca	gcttgcgt	ggtggcatcg	5700
cgcggacac	gctgaacttg	tggccgttta	cgtcgccgtc	cagtcgacc	5760

V082.ST25.txt

ccacccccgt	gaacagctcc	tcgcccgtgc	tcaccatgtc	ggccgaggat	aatgata	5820		
gaagtaaaa	gatgaaaaag	agaaaaagat	tagtcttac	catggctatc	gttcgtaaat	5880		
ggtaaaatt	ttcagaaaat	agcttttgc	ttaaaaagaaa	tgat	ttaaat	tgctgc	aata	5940
gaagtagaat	gcttgcattgc	tttagattcg	tttgcattgt	atatgttgc	ttgagaattc	6000		
gagtcggt	cccggggatc	ctctagcgaa	tttgcattgc	tcaaattgtt	gagggttagcg	6060		
gat	ttgtaaa	cgcgttata	tgggctgctt	ggagggtact	tttggattaa	ttttttctg	6120	
ccagcgcatt	ctgacgcggc	accgcattgg	aaagtgcgt	gtgggtccgc	gtttctaca	6180		
ataatgtgcc	gatccggtca	gaaagtata	ggatgagttg	tgccagcctc	accaacgtgc	6240		
tgcaggccca	tcatgactac	ttcaatgtt	atgggggtaa	tgaataaata	ggcgaaattg	6300		
gttca	cggt	gggcccagg	aatataat	tgccgcagag	gtagtcggat	gccaaggccc	6360	
gcaactaata	gttcacgaac	aaattcctag	agagtcgacc	tgcagcatgc	aagctaacct	6420		
gcaggcatgc	aagcttagct	tgagcttgc	tcagattgc	tttccgc	ttcagttaa	6480		
actatcagt	tttgacagga	tatattggcg	ggttacacca	agagaaaaga	gcgttattt	6540		
gaataacgga	tat	ttaaaag	ggcgtaaaa	ggttatccg	ttcgtccatt	tgtatgtc	6600	
tgccaaccac	agggttcccc	tcgggatcaa	agtacttgc	tccaaacccct	ccgctgctat	6660		
agtgcagtcg	gttctgacg	ttcagtgcag	ccgttctgc	aaaacgacat	gtcgcacaag	6720		
tcctaagtta	cgcgcacaggc	tgccgcctg	ccctttcct	ggcgtttct	tgtcgctgt	6780		
tttagtcgca	taaagttagaa	tacttgcac	tagaaccgga	gacattacgc	catgaacaag	6840		
agcgcgcgc	ctggcctgct	gggctatgcc	cgcgtcagca	ccgacgacca	ggacttgcac	6900		
aaccaacggg	ccgaactgca	cgcggccggc	tgcacca	tggttccga	gaagatcacc	6960		
ggcaccaggc	gcgaccgccc	ggagctggcc	aggatgttgc	accacctacg	ccctggcgac	7020		
gttgcacag	tgaccaggct	agaccgcctg	gcccgcagca	cccgcgac	actggacatt	7080		
gccgagcgca	tccaggaggc	cggcgcgggc	ctgcgtagcc	tggcagagcc	gtggccgcac	7140		
accaccacgc	cggcggccgc	catggtgttgc	accgtgttgc	ccggcattgc	cgagttcgag	7200		
cgttccctaa	tcatcgaccg	cacccggagc	gggcgcgagg	ccgccaaggc	ccgaggcgtg	7260		
aagtttggcc	cccgccctac	cctcaccccg	gcacagatcg	cgcacgccc	cgagctgatc	7320		
gaccaggaag	gccgcaccgt	gaaagaggcg	gctgcactgc	ttggcgtgc	tgcgtcgacc	7380		
ctgtaccgcg	cacttgagcg	cagcgaggaa	gtgacgccc	ccgaggcc	gcggcgcgg	7440		
gccttccgt	aggacgcatt	gaccgaggcc	gacgcctgg	cgccgc	ccgaaatgc	7500		
caagaggaac	aagcatgaaa	ccgcaccagg	acggccagga	cgaaccgttt	ttcattaccg	7560		
aagagatcg	ggcggagatg	atcgccggcg	ggtacgttgc	cgagccccc	gcgcacgtct	7620		
caaccgtcg	gtcgcatgaa	atccctggcc	gtttgtctga	tgc	ccaaagctg	gcggcctggc	7680	
cgccca	gcttgcgt	gaaaccgagc	gccgcgtct	aaaaaggtga	tgttat	ttg	7740	
agtaaaacag	cttgcgtcat	gcggcgtct	cgtatatgt	gcgtatgagta	aataaaca	aa	7800	

V082.ST25.txt

tacgcaagggaaacgcatga	aggttatcgctgtacttaac	cagaaaggcg	ggtcaggcaa	7860		
gacgaccatc	gcaacccatc	tagcccgcgc	cctgcaactc	gccggggccg	atgttctgtt	7920
agtcgattcc	gatccccagg	gcagtgcgg	cgatggcg	gccgtgcggg	aagatcaacc	7980
gctaaccgtt	gtcggcatcg	accgcccac	gattgaccgc	gacgtgaagg	ccatcgccg	8040
gcgcgacttc	gtagtgtatcg	acggagcgc	ccaggcggcg	gacttggctg	tgtccgcgt	8100
caaggcagcc	gacttcgtgc	tgattccgt	gcagccaagc	ccttacgaca	tatggccac	8160
cgccgacctg	gtggagctgg	ttaagcagcg	cattgaggc	acggatggaa	ggctacaagc	8220
ggccttgc	gtgtcgccgg	cgatcaaagg	cacgcgcate	ggcgggtgagg	ttgcgcaggc	8280
gctggccggg	tacgagctgc	ccattcttga	gtcccgatc	acgcagcgcg	tgagctaccc	8340
aggcactgcc	gccgcggca	caaccgttct	tgaatcagaa	cccgaggcg	acgctgccc	8400
cgaggtccag	gcgcgtggccg	ctgaaattaa	atcaaactc	atttgagtt	atgaggtaaa	8460
gagaaaaatga	gcaaaagcac	aaacacgcta	agtgcggcc	gtccgagcgc	acgcagcgc	8520
aaggctgcaa	cgttggccag	cctggcagac	acgcgcagca	tgaagcgggt	caacttcag	8580
ttgccggccg	aggatcacac	caagctgaag	atgtacgcgg	tacgccaagg	caagaccatt	8640
accgagctgc	tatctgaata	catcgccag	ctaccagagt	aatgagcaa	atgaataat	8700
gagtagatga	attttagcgg	ctaaaggagg	cgcatggaa	aatcaagaac	aaccaggcac	8760
cgacccgtg	aatgccccca	tgtgtggagg	aacggccgt	tggccaggcg	taagcggctg	8820
ggttgtctgc	cggccctgca	atggcactgg	aacccccaag	cccgaggaat	cggcgtgacg	8880
gtcgcaaacc	atccggcccg	gtacaaatcg	gcgcggcgct	gggtgatgac	ctggtgagaa	8940
agttgaaggc	cgcgcaggcc	gcccagcggc	aacgcatacg	ggcagaagca	cgccccggtg	9000
aatcgtggca	agcggccgct	gatcgaatcc	gcaaagaatc	ccggcaaccg	ccggcagccg	9060
gtgcggcgtc	gatttaggaag	ccgccaagg	gcgcagcgc	accagatttt	ttcgttccga	9120
tgctctatga	cgtgggcacc	cgcgatagtc	gcagcatcat	ggacgtggcc	gtttccgtc	9180
tgtcgaagcg	tgaccgacga	gctggcgagg	tgatccgcta	cgagcttcca	gacgggcacg	9240
tagagtttc	cgcagggccg	gccggcatgg	ccagtgtgt	ggattacgac	ctggtaactga	9300
tggcggtttc	ccatctaacc	gaatccatga	accgataccg	ggaagggaaag	ggagacaagc	9360
ccggccgcgt	gttccgtcca	cacgttgcgg	acgtactcaa	gttctgccgg	cgagccgatg	9420
gcggaaagca	gaaagacgac	ctggtagaaa	cctgcattcg	gttaaacacc	acgcacgtt	9480
ccatgcagcg	tacgaagaag	gccaagaacg	gccgccttgt	gacggtatcc	gagggtgaag	9540
ccttgattag	ccgctacaag	atcgtaaaga	gcgaaaccgg	gcggccggag	tacatcgaga	9600
tcgagctagc	tgattggatg	taccgcgaga	tcacagaagg	caagaacccg	gacgtgctga	9660
cggttccatcc	cgattacttt	ttgatcgatc	ccggcatcg	ccgtttctc	taccgcctgg	9720
cacgccgcgc	cgcaggcaag	gcagaagcca	gatggttgtt	caagacgatc	tacgaacgca	9780
gtggcagcgc	cggagagttc	aagaagttct	gtttcaccgt	gkgcaagctg	atcgggtcaa	9840

V082.ST25.txt

atgacctgcc	ggagtacgat	ttgaaggagg	aggcgggca	ggctggccc	atcctagtca	9900
tgcgctaccg	caacctgatc	gagggcgaag	catccgcgg	ttcctaattgt	acggagcaga	9960
tgcttagggca	aattgccta	gcagggaaa	aaggtcgaa	aggtctctt	cctgtggata	10020
gcacgtacat	tgggaaccca	aagccgtaca	ttgggaaccg	gaacccgtac	attgggaacc	10080
caaagccgt	cattggAAC	cggtcacaca	tgttaagtgc	tgtatataaa	gagaaaaaag	10140
gcgatTTTC	cgcctaaaac	tcttAAAC	ttatTAAC	tcttAAAC	cgcctggcct	10200
gtgcataact	gtctggccag	cgcacagccg	aagagctgca	aaaagcgcct	acccttcggt	10260
cgctgcgctc	cctacgcccc	gccgcttcgc	gtcggcctat	cgcggccgct	ggccgctcaa	10320
aaatggctgg	cctacggcca	ggcaatctac	cagggcgcgg	acaagccgcg	ccgtcgccac	10380
tcgaccgcgc	gcccacat	caaggcaccc	tgcctcgcgc	gttccggta	tgacggtaaa	10440
aacctctgac	acatgcagct	cccggagacg	gtcacagctt	gtctgtaa	ggatgcccgg	10500
agcagacaag	cccgtcaggg	cgcgtcageg	ggtgttgcgc	ggtgtcgggg	cgcagccatg	10560
acccagtcac	gtagcgatag	cgaggtgtat	actggctta	ctatgcggca	tcagagcaga	10620
ttgtactgag	agtgcaccat	atgcggtgt	aaataccgca	cagatgcgt	aggagaaaat	10680
accgcacatc	gacgtcttcc	gttcctcg	tcactgactc	gctgcgtcg	gtcggtcg	10740
tgccgcgagc	ggtatcagct	cactcaaagg	cggtaatacg	gttatccaca	gaatcagggg	10800
ataacgcagg	aaagaacatg	tgagcaaaag	gccagcaaaa	ggccaggaac	cgtaaaaagg	10860
ccgcgttgct	ggcgTTTT	cataggctcc	gccccctga	cgagcatcac	aaaaatcgac	10920
gctcaagtca	gaggtggcga	aaccgcacag	gactataaag	ataccaggcg	tttccccctg	10980
gaagctccct	cgtgcgtct	cctgttccga	ccctgccc	tacggatac	ctgtccgc	11040
ttctcccttc	gggaagcgtg	gcgtttctc	atagctcacg	ctgttaggtat	ctcagttcgg	11100
tgttaggtcg	tcgtccaag	ctgggctgt	tgcacgaacc	ccccgttc	cccgaccgct	11160
gcgccttatac	cggtaactat	cgtcttgagt	ccaacccgt	aagacacgac	ttatgcac	11220
tggcagcagc	cactggtaac	aggattagca	gagcgaggta	tgtaggcggt	gtcacagagt	11280
tcttgaagt	gtggccta	tacggctaca	ctagaaggac	agtatttgg	atctgcgtc	11340
tgctgaagcc	agttaccttc	ggaaaaagag	ttggtagctc	ttgatccggc	aaacaaacca	11400
ccgctggtag	cggggTTT	tttggggca	agcagcagat	tacgcgcaga	aaaaaaggat	11460
ctcaagaaga	tcctttgatc	ttttctacgg	ggtctgacgc	tca	gatggaa	11520
gttaaggat	tttggtcatg	catgatatat	ctcccaattt	gtgttagggct	tattatgcac	11580
gctaaaaat	aataaaagca	gacttgacct	gatagttgg	ctgtgagcaa	ttatgtgctt	11640
agtgcacatcta	atcgcttgag	ttaacgcgg	cgaagcggcg	tcggcttga	cgaatttcta	11700
gctagacatt	atttgcgcac	taccttggtg	atctgcctt	tca	cgttagtg	11760
tccaaactgat	ctgcgcgcga	ggccaagcga	tcttcttctt	gtccaagata	agcctgtcta	11820
gcttcaagta	tgacgggctg	atactggcc	ggcaggcgct	ccattgc	ccgcagcg	11880

V082.ST25.txt

acatccctcg	gcfgatttt	gccggtaact	gcgcgttacc	aaatgcggga	caacgtaagc	11940
actacatttc	gctcatcgcc	agcccagtctg	ggcgccgagt	tccatagcgt	taaggttca	12000
tttagcgcct	caaatacgatc	ctgttcagga	accggatcaa	agagttcctc	cggcgcttgg	12060
cctacccaagg	caacgctatg	ttctcttgct	tttgcagca	agatagccag	atcaatgtcg	12120
atcgtggctg	gctcgaagat	acctgcaaga	atgtcattgc	gctgccattc	tccaaattgc	12180
atgtcgct	tagctggata	acgccacgga	atgatgtcgt	cgtgcacaac	aatggtact	12240
tctacagcgc	ggagaatctc	gctctctcca	ggggaaagccg	aagtttccaa	aaggtcgttg	12300
atcaaagctc	gccgcgttgt	ttcatcaagc	cttacggtca	ccgttaaccag	caaataata	12360
tcactgtgtg	gcttcaggcc	gccatccact	gccccggcgt	acaaatgtac	ggccagcaac	12420
gtcggttcga	gatggcgctc	gatgacgcca	actacctctg	atagttgagt	cgataactcg	12480
gcatcaccg	cttccccat	gatgtttaac	tttggggtag	ggcgactgcc	ctgctgcgt	12540
acatcggtgc	tgctccataa	catcaaacat	cgacccacgg	cgtaacgcgc	ttgctgcttg	12600
gatgcccgg	gcatagactg	tacccaaaaa	aaacatgtca	taacaagaag	ccatgaaaac	12660
cgccactgcg	ccgttaccac	cgctgcgttc	ggtaagggtt	ctggaccagt	tgcgtgacgg	12720
cagttacgt	acttgcatta	cagttacga	accgaacgag	gcttatgtcc	actgggttcg	12780
tgccccaat						12789
<210>	10					
<211>	20					
<212>	DNA					
<213>	Artificial Sequence					
<220>						
<223>	degenerate primer ALGG39					
<220>						
<221>	misc_feature					
<222>	(3)..(3)					
<223>	Inosine					
<220>						
<221>	misc_feature					
<222>	(9)..(9)					
<223>	Inosine					
<220>						
<221>	misc_feature					
<222>	(11)..(11)					
<223>	Inosine					
<220>						
<221>	misc_feature					
<222>	(15)..(15)					
<223>	g or a					
<220>						
<221>	misc_feature					
<222>	(18)..(18)					

V082.ST25.txt

<223> any base

<400> 10
ccargykcag gaaaracnac

20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence<220>
<223> degenerate primer ALGG40<220>
<221> misc_feature
<222> (3)..(3)
<223> Inosine<220>
<221> misc_feature
<222> (15)..(15)
<223> any base<220>
<221> misc_feature
<222> (18)..(18)
<223> any base<400> 11
acackytttyt tytgncncc

20

<210> 12
<211> 8
<212> DNA
<213> Artificial Sequence<220>
<223> degenerate primer ALGG41<220>
<221> misc_feature
<222> (6)..(6)
<223> any base<220>
<221> misc_feature
<222> (5)..(5)
<223> g or a<220>
<221> misc_feature
<222> (3)..(3)
<223> any base<400> 12
tcnarncc

8

<210> 13

V082.ST25.txt

```
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate primer ALGG42

<220>
<221> misc_feature
<222> (3)..(3)
<223> Inosine

<220>
<221> misc_feature
<222> (6)..(6)
<223> Inosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> Inosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> Inosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> any base

<220>
<221> misc_feature
<222> (18)..(18)
<223> any base

<400> 13
ggagtaytaa cagcnytnat ggg
```

23

```
<210> 14
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate primer ALGG43

<220>
<221> misc_feature
<222> (3)..(3)
<223> any base

<220>
<221> misc_feature
<222> (18)..(18)
<223> any base

<220>
```

V082.ST25.txt

<221> misc_feature
<222> (5)..(5)
<223> g or a

<220>
<221> misc_feature
<222> (21)..(21)
<223> g or a

<220>
<221> misc_feature
<222> (12)..(12)
<223> Inosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> Inosine

<400> 14
tcnarcatcc aagtagcngg rtt

23

<210> 15
<211> 8
<212> DNA
<213> Artificial Sequence

<220>
<223> degenerate primer ALGG44

<220>
<221> misc_feature
<222> (6)..(6)
<223> g or a

<400> 15
ckccarta

8